

Application Data Sheet

Application Information

Application Type:: Regular
Subject Matter:: Utility
Suggested Group Art Unit:: Not Yet Assigned
CD-ROM or CD-R?:: None
Sequence submission?:: None
Computer Readable Form (CRF)?:: No
Title:: METHODS OF TREATMENT USING
AMMONIA-SCAVENGING DRUGS

Attorney Docket Number:: 643982000100
Request for Early Publication?:: No
Request for Non-Publication?:: No
Total Drawing Sheets:: 15
Small Entity?:: Yes
Petition included?:: No
Secrecy Order in Parent Appl.?:: No

Applicant Information

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Bruce
Family Name:: SCHARSCHMIDT
City of Residence:: South San Francisco
State or Province of Residence:: CA
Country of Residence:: US
Street of mailing address:: 601 Gateway Blvd. Ste. 200

City of mailing address:: South San Francisco
State or Province of mailing address:: CA
Postal or Zip Code of mailing address:: 94080

Correspondence Information

Correspondence Customer Number:: 25225

Representative Information

Representative Customer Number:: 25225

Domestic Priority Information

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
This Application	An application claiming the benefit under 35 USC 119(e)	61/093,234	08/29/08

Foreign Priority Information

Assignee Information

Claims

1. A method to determine an effective dosage of HPN-100 for a patient in need of treatment for a nitrogen retention disorder, which comprises monitoring the effect of an initial dosage of HPN-100,
wherein monitoring the effect consists essentially of determining the patient's urinary phenylacetyl glutamine (PAGN) output;
and determining from the urinary PAGN output whether and/or how to adjust the initial dosage of HPN-100 to produce a desired ammonia scavenging effect.
2. The method of claim 1, wherein urinary PAGN output is determined as a ratio of the concentration of urinary PAGN to urinary creatinine.
3. The method of claim 1, wherein the nitrogen retention disorder is chronic hepatic encephalopathy or a urea cycle disorder.
4. The method of claim 1, wherein administering the effective dosage of HPN-100 to the patient produces a normal plasma ammonia level in the patient.
5. A method to determine an effective dosage of HPN-100 for a patient in need of treatment for a nitrogen retention disorder, which comprises monitoring the effect of an initial dosage of HPN-100,
wherein monitoring the effect consists of determining the patient's urinary phenylacetyl glutamine (PAGN) output and/or total urinary nitrogen.
6. A method to determine a dosage of HPN-100 for a patient having a nitrogen retention disorder, which comprises calculating the dosage of HPN-100 based on a utilization efficiency for HPN-100 conversion into PAGN of about 60% to about 75%.
7. The method of claim 6, wherein the dosage of HPN-100 is calculated from the patient's dietary protein intake.

8. The method of claim 7, wherein the dosage of HPN-100 is reduced to account for the patient's residual urea synthesis capacity.
9. A method to determine a dosage of a PAA prodrug for a patient having an ammonia retention disorder, comprising:
 - a) determining the patient's residual urea synthesis capacity;
 - b) determining the patient's dietary protein intake;
 - c) estimating from a) and b) the patient's target urinary PAGN output;
 - d) determining an amount of the PAA prodrug needed to produce the target amount of urinary PAGN,
wherein about 60% to about 75% of the PAA prodrug is converted into urinary PAGN.
10. The method of claim 9, wherein the PAA prodrug is phenylbutyric acid (PBA) or a pharmaceutically acceptable salt thereof.
11. The method of claim 9, wherein the PAA prodrug is HPN-100.
12. A method to treat a patient having an ammonia retention disorder with a suitable dosage of a PAA prodrug, comprising:
 - a) determining the patient's residual urea synthesis capacity;
 - b) determining the patient's dietary protein intake;
 - c) estimating from a) and b) the patient's target urinary PAGN output;
 - d) determining an amount of the PAA prodrug needed to mobilize the target amount of urinary PAGN based on about 60% to about 75% conversion of the PAA prodrug into urinary PAGN; and
 - e) administering to the patient the suitable dosage of the PAA prodrug.
13. The method of claim 12, wherein the PAA prodrug is phenylbutyrate or a pharmaceutically acceptable salt thereof, or HPN-100.

14. The method of claim 12, wherein the PAA prodrug is HPN-100, the patient is a patient with clinically significant residual urea synthetic capacity, and the HPN-100 is administered in two or three doses per day.

15. A method to transition a patient receiving treatment with an initial amount of phenylacetate or phenylbutyrate to a final amount of HPN-100, comprising:

determining a replacement amount of HPN-100 to replace at least a portion of the phenylacetate or phenylbutyrate;

substituting the replacement amount of the HPN-100 for the phenylacetate or phenylbutyrate; and

monitoring the amount of urinary PAGN excreted by the patient to assess the effectiveness of the replacement amount of the HPN-100.

16. The method of claim 15, wherein an increase in the amount of urinary PAGN caused by the transition indicates that the amount of HPN-100 can be reduced.

17. A method to transition a patient taking an initial daily dosage of phenylbutyrate from phenylbutyrate to HPN-100, comprising

a) determining a suitable amount of HPN-100 to replace at least a portion of the initial daily dosage of phenylbutyrate;

b) administering the suitable amount of HPN-100 to the subject along with an amount of phenylbutyrate corresponding to the initial daily dosage of phenylbutyrate minus an amount corresponding to the portion replaced by HPN-100;

c) determining the level of excreted urinary PAGN for the subject; and

d) repeating steps a-c until all of the phenylbutyrate is replaced by HPN-100.

18. A method to initiate treatment with phenylacetate, phenylbutyrate or a HPN-100 in a step-wise fashion, comprising:

- a) estimating or measuring dietary nitrogen intake for the patient;
and/or
- b) estimating the patient's need for urinary waste nitrogen excretion based upon diet and urea synthetic capacity; then
- c) administering a starting dose of the drug estimated to provide a fraction of the necessary waste nitrogen clearance as urinary PAGN taking into account an estimated 60% to 75% conversion of the administered drug into PAGN; and
- d) increasing the dose of drug as appropriate, and repeating the steps above, to reach a maintenance dose of the drug.

19. A method to treat a UCD patient with a PBA prodrug, wherein the prodrug produces equivalent or better ammonia level control compared to PBA without increasing the patient's exposure to PBA as judged by the AUC and Cmax for PBA when the patient receives the PBA prodrug, when compared to the AUC and Cmax observed when the patient receives an equimolar amount of PBA.

20. The method of claim 19, wherein the PBA prodrug is HPN-100.

21. The method of claim 20, wherein the AUC for PBA exposure is lower with the prodrug than with PBA by at least about 20%.

22. The method of claim 20, wherein the exposure to PBA upon treatment with the prodrug is lower by at least about 30% compared to treatment with PBA.

23. A method to determine a suitable dietary protein level for a patient having a nitrogen retention disorder, comprising:

- determining the patient's endogenous nitrogen elimination capacity;
- calculating from the endogenous nitrogen elimination capacity an amount of dietary protein the patient can process without the aid of a nitrogen scavenging drug;

then adding an amount of protein that the patient should be able to process with the assistance of selected dosage of a nitrogen scavenging drug to arrive at an amount of dietary protein the patient can have while being treated with the selected dosage of the nitrogen scavenging drug, taking into account the of protein required for health and body growth.

24. The method of claim 23, wherein the nitrogen scavenging drug is HPN-100.

25. The method of claim 24, wherein the selected dosage of HPN-100 is up to about 19 grams per day, and wherein the amount of dietary protein the patient should be able to process with the assistance of this amount of HPN-100 is about 1 g of protein per gram of HPN-100.

26. A method to treat a patient with a PBA prodrug, comprising administering HPN-100 at a daily dose in excess of 19 g per day to a subject having HE or UCD.

27. The method of claim 26, wherein the daily dose of HPN-100 is between about 19g and about 57 g.

28. A method to treat a patient having a nitrogen retention disorder with the PBA prodrug HPN-100, wherein the AUC for PBA is less than about 600 and the C_{max} for PBA is less than about 100 when the PBA prodrug is administered.

29. The method of claim 28, wherein the subject's plasma ammonia levels are on average normal when treated with HPN-100.

Abstract of the Disclosure

The invention provides a method for determining a dose and schedule and making dose adjustments of PBA prodrugs used to treat nitrogen retention states, or ammonia accumulation disorders, by measuring urinary excretion of phenylacetylglutamine and/or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered ammonia scavenging drug.

Figure 2

A conventional clinical pharmacology model in which only drug reaching the central (systemic) circulation is assumed to be active.





FIGURE 4



In each panel, the curves represent measured levels of PBA, PAA or PAGN in subjects receiving BUPHENYL® (sodium phenylbutyrate) (sodium PBA) at 3g/m² dosage, or HPN-100 in an amount calculated to provide an equimolar amount of PBA to that provided by the sodium PBA dosage. Three curves for each material are for three subjects who received the specified dosages of sodium PBA or HPN-100. In the left panel, the upper curve represents PBA levels; the intermediate one represents PAA levels; and the lowest of the three sets of lines represents PAGN levels. In the right panel, the three lowest curves at the 10-15 hour time span are all for PBA; and the highest three curves at 15-25 hours represent PAGN levels. PAA levels were not determined after approximately 12 hours, and fall generally close to the PAGN curves up to that time.

Figure 5

Relationship between blood ammonia levels (partial time-normalized area under the curve [partial AUC]) and urinary output of PAGN in 10 subjects during steady state treatment with HPN-100 or sodium PBA. Partial AUCs are plotted against the corresponding time of the urine collection, which ranged from 6 to 12 hours.





FIGURE 6



Schematic anatomic depiction of the systemic and presystemic (represented by the portal vein) compartments. Unlike the case for most drugs which need to pass through the liver to the systemic circulation to exert an effect, PAA converted to PAGN prior to reaching the systemic circulation (e.g. in the liver) is still effective in clearing ammonia from the body.

Figure 7




Figure 8




Figure 9a

Figure 9 depicts the lack of correlation between drug dose and plasma PBA (9a) and plasma PAA (9b), as compared with a significant correlation with urinary output of PAGN (9c).




Figure 9b




Figure 9c




Figure 10





Figure 11

Cumulative Ammonia Concentration TN-AUC



Plasma ammonia levels (time-normalized area under the curve [TN-AUC or AUC]) during the day and night in 10 UCD patients treated for seven days with either sodium PBA (BUP) or a PBA equimolar dose of HPN-10.

FIGURE 12

Plasma ammonia levels (time-normalized area under the curve [TN-AUC]) in 10 UCD patients treated for seven days with sodium PBA (BUP) followed by seven days with a PBA equimolar dose of HPN-100.





Figure 13

Ammonia (TN-AUC) After 7 days of Treatment
with BUPHENYL and HPN-100



Mean plasma ammonia levels (time-normalized area under the curve [TN-AUC]) in 10 UCD patients treated for seven days with sodium PBA followed by seven days with a PBA equimolar dose of HPN-100.

Electronic Acknowledgement Receipt

EFS ID:	4573755
Application Number:	12350111
International Application Number:	
Confirmation Number:	6290
Title of Invention:	METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS
First Named Inventor/Applicant Name:	Bruce SCHARSCHMIDT
Customer Number:	25225
Filer:	Michael Glenn Smith/Jessica Conen
Filer Authorized By:	Michael Glenn Smith
Attorney Docket Number:	643982000100
Receipt Date:	07-JAN-2009
Filing Date:	
Time Stamp:	18:58:05
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$1686
RAM confirmation Number	5591
Deposit Account	031952
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 24 (Patent application and reexamination processing fees)

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	643982000100TRANS.pdf	38846 de576e6b5231fb325a135da83887b8621bc514cd	no	1
Warnings:					
Information:					
2	Application Data Sheet	643982000100ADS.pdf	15832 08ec20303601a708a26e7642840ad4a92d1b8714	no	2
Warnings:					
Information:					
This is not an USPTO supplied ADS fillable form					
3		643982000100SPEC.pdf	933900 fab8e781c3567b4f0031b23474db7548af103dc8	yes	75
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Specification		1	54	
	Claims		55	60	
	Drawings-only black and white line drawings		61	75	
Warnings:					
Information:					
4	Fee Worksheet (PTO-06)	fee-info.pdf	38054 e60deb2d40b709c5e8f9798c00a1dac4606e24c7	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			1026632		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Patent Application Fee Transmittal

Application Number:				
Filing Date:				
Title of Invention:	METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS			
First Named Inventor/Applicant Name:	Bruce SCHARSCHMIDT			
Filer:	Michael Glenn Smith/Jessica Conen			
Attorney Docket Number:	643982000100			
Filed as Small Entity				
Utility under 35 USC 111(a) Filing Fees				
Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Utility filing Fee (Electronic filing)	4011	1	82	82
Utility Search Fee	2111	1	270	270
Utility Examination Fee	2311	1	110	110
Pages:				
Claims:				
Claims in excess of 20	2202	9	26	234
Independent claims in excess of 3	2201	9	110	990
Miscellaneous-Filing:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
			Total in USD (\$)	1686

Filing Date: 01/07/09

Approved for use through 7/31/2006. OMB 0651-0032
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD					Application or Docket Number						
Substitute for Form PTO-875					12/350,111						
APPLICATION AS FILED – PART I					SMALL ENTITY		OR		OTHER THAN SMALL ENTITY		
(Column 1)		(Column 2)			RATE (\$)	FEE (\$)			RATE (\$)	FEE (\$)	
FOR	NUMBER FILED	NUMBER EXTRA			N/A	82			N/A		
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A			N/A	270			N/A		
SEARCH FEE (37 CFR 1.16(k), (l), or (m))	N/A	N/A			N/A	110			N/A		
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A			x\$26	234	OR		x\$52		
TOTAL CLAIMS (37 CFR 1.16(i))	29	minus 20 = 9			x\$110	990	OR		x\$220		
INDEPENDENT CLAIMS (37 CFR 1.16(h))	12	minus 3 = 9					OR				
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$260 (\$130 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR						OR				
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					195		OR		390		
					TOTAL	1686	OR		TOTAL		
* If the difference in column 1 is less than zero, enter "0" in column 2.											
APPLICATION AS AMENDED – PART II					SMALL ENTITY		OR		OTHER THAN SMALL ENTITY		
(Column 1)		(Column 2)		(Column 3)	RATE (\$)	ADDITIONAL FEE (\$)			RATE (\$)	ADDITIONAL FEE (\$)	
AMENDMENT A	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	X =		OR		X =		
	Total (37 CFR 1.16(i))	*	Minus **	=	X =		OR		X =		
	Independent (37 CFR 1.16(h))	*	Minus ***	=			OR				
	Application Size Fee (37 CFR 1.16(s))					N/A		OR		N/A	
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					TOTAL ADD'T FEE		OR		TOTAL ADD'T FEE	
(Column 1)		(Column 2)		(Column 3)	SMALL ENTITY		OR		OTHER THAN SMALL ENTITY		
AMENDMENT B	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	X =		OR		X =		
	Total (37 CFR 1.16(i))	*	Minus **	=	X =		OR		X =		
	Independent (37 CFR 1.16(h))	*	Minus ***	=			OR				
	Application Size Fee (37 CFR 1.16(s))					N/A		OR		N/A	
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					TOTAL ADD'T FEE		OR		TOTAL ADD'T FEE	
* If the entry in column 1 is less than the entry in column 2, write "0" in column 3. ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20". *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3". The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.											

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DocCode - SCORE

SCORE Placeholder Sheet for IFW Content

Application Number: 12350111 Document Date: 1/7/2009

The presence of this form in the IFW record indicates that the following document type was received in paper and is scanned and stored in the SCORE database.

- Design Drawings

The original paper documents are in the physical artifact folder. The original documents are scanned using a higher quality capture process and stored in SCORE. A copy of these documents are scanned in IFW using the standard quality scanning process. Defects visible in both IFW and SCORE are indicative of defects in the original paper documents.

To access the documents in the SCORE database, refer to instructions developed by SIRA.

At the time of document entry (noted above):

- Examiners may access SCORE content via the eDAN interface.
- Other USPTO employees can bookmark the current SCORE URL (<http://es/ScoreAccessWeb/>).
- External customers may access SCORE content via the Public and Private PAIR interfaces.

Form Revision Date: October 12, 2006

METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS

Cross-Reference to Related Applications

[0001] This application claims benefit of priority to U.S. Provisional application serial number 61/093,234, filed August 29, 2008, which is incorporated herein by reference in its entirety. This application is also related to the U.S. provisional patent application entitled "Treating special populations having liver disease with nitrogen-scavenging compounds," naming Sharron Gargosky as inventor, serial number 61/048,830, filed on April 29, 2008.

Technical Field

[0002] This invention relates to treatment of patients with nitrogen retention states, in particular urea cycle disorders (UCDs) and cirrhosis complicated by hepatic encephalopathy (HE), using administered compounds that assist in elimination of waste nitrogen from the body. The compounds can be orally administered small-molecule drugs, and the invention provides methods for delivering these compounds and selecting suitable dosages for a patient.

Background Art

[0003] Drug dosing is usually based upon measurement of blood levels of the active drug species in conjunction with clinical assessment of treatment response. However, the present invention is based on evidence that for certain prodrugs of phenylacetic acid (PAA), measuring the blood level of the prodrug (e.g. PBA) or of PAA formed from it is unreliable. In addition, assessment of treatment effect by measuring levels of ammonia in the blood is inconvenient, because it requires withdrawing multiple blood samples under carefully controlled conditions. Because blood ammonia levels are affected by various factors including dietary protein, they also fail to provide a direct measure of how much ammonia the drug is mobilizing for elimination. The invention demonstrates that prodrugs of phenylbutyric acid (PBA) behave similarly to sodium PBA, in that measuring PBA levels is unreliable for assessing their effectiveness. This invention provides a novel method for dosing in patients with nitrogen retention states, in particular patients with liver disease and clinical manifestations of hepatic encephalopathy and patients with UCDs. It is particularly applicable to prodrugs that liberate or are metabolized to form phenylacetic acid, i.e., prodrugs of PAA, and those prodrugs that are metabolized to form PBA.

[0004] Hepatic encephalopathy refers to a spectrum of neurologic signs and symptoms which frequently occur in patients with cirrhosis or certain other types of liver disease.

[0005] Urea cycle disorders comprise several inherited deficiencies of enzymes or transporters necessary for the synthesis of urea from ammonia. The urea cycle is depicted in Figure 1, which also illustrates how certain ammonia-scavenging drugs act to assist in elimination of excessive ammonia. The enzymes including their Enzyme Commission (EC) numbers and modes of inheritance include the following:

- Carbamyl phosphate synthetase (CPS; EC Number 6.3.4.16; autosomal recessive),
- ornithine transcarbamylase (OTC; EC Number 2.1.3.3; X-linked),
- argininosuccinate synthetase (ASS; EC Number 6.3.4.5; autosomal recessive),
- argininosuccinate lyase (ASL; EC Number 4.3.2.1; autosomal recessive),
- arginase (ARG; EC Number 3.5.3.1; autosomal recessive), and
- N-acetyl glutamine synthetase (NAGS 1; EC Number 2.3.1.1; autosomal recessive)

[0006] Mitochondrial transporter deficiency states which mimic many features of urea cycle enzyme deficiencies include the following:

- Ornithine translocase deficiency (hyperornithinemia, hyperammonemia, homocitrullinuria or HHH Syndrome)
- Citrin (aspartate glutamate transporter) deficiency

[0007] The common feature of UCD and hepatic encephalopathy that render them treatable by methods of the invention is an accumulation of excess waste nitrogen in the body, and hyperammonemia. In normal individuals, the body's intrinsic capacity for waste nitrogen excretion is greater than the body's waste nitrogen production, so waste nitrogen does not accumulate and ammonia does not build up to harmful levels. For patients with nitrogen retention states such as UCD or HE, the body's intrinsic capacity for waste nitrogen excretion is less than the body's waste nitrogen production based on a normal diet that contains significant amounts of protein. As a result, nitrogen builds up in the body of a patient having a nitrogen retention disorder, and usually results in excess ammonia in the blood. This has various toxic effects; drugs that help eliminate the excess ammonia are an important part of an overall management strategy for such disorders.

[0008] To avoid build-up of ammonia to toxic levels in patients with nitrogen retention states, dietary intake of protein (a primary source of exogenous waste nitrogen) must be balanced by the

patient's ability to eliminate excess ammonia. Dietary protein can be limited, but a healthy diet requires a significant amount of protein, particularly for growing children; thus in addition to controlling dietary protein intake, drugs that assist with elimination of nitrogen are used to reduce ammonia build-up (hyperammonemia). The capacity to eliminate excess ammonia in treated patients can be considered the sum of the patient's endogenous capacity for nitrogen elimination (if any) plus the amount of additional nitrogen-elimination capacity that is provided by a nitrogen scavenging drug. The methods of the invention use a variety of different drugs that reduce excess waste nitrogen and ammonia by converting it to readily-excreted forms, such as phenylacetyl glutamine (PAGN). In some embodiments, the invention relates to methods for determining or adjusting a dosage of an oral drug that forms PAA *in vivo*, which is converted into PAGN, which is then excreted in urine and thus helps eliminate excess nitrogen.

[0009] Based on prior studies in individual UCD patients (e.g. Brusilow, Pediatric Research, vol. 29, 147-50 (1991); Brusilow and Finkelstien, J. Metabolism, vol. 42, 1336-39 (1993)) in which 80-90% of the nitrogen scavenger sodium phenylbutyrate was reportedly excreted in the urine as PAGN, current treatment guidelines typically either assume complete conversion of sodium phenylbutyrate or other PAA prodrugs to PAGN (e.g. Berry et al., J. Pediatrics, vol. 138, S56-S61 (2001)) or do not comment on the implications of incomplete conversion for dosing (e.g. Singh, Urea Cycle Disorders Conference Group '*Consensus Statement from a Conference for the Management of Patients with Urea Cycle Disorders*', Suppl to J Pediatrics, vol. 138(1), S1-S5 (2001)).


[0010] Current treatment guidelines recommend 4 times per day dosing, based on the fact that PBA is absorbed rapidly from the intestine when administered in the form of sodium PBA and exhibits a short half life in the bloodstream (Urea Cycle Disorders Conference Group '*Consensus Statement*' 2001)

[0011] Current recommendations for sodium phenylbutyrate dosing indicate that dosage should not exceed 600 mg/kg (for patients weighing up to 20 kg) or in any case 20 grams total.

Disclosure of Embodiments of the Invention

[0012] The invention provides a novel approach for determining and adjusting the schedule and dose of orally administered nitrogen scavenging drugs, including sodium phenylbutyrate and glyceryl tri-[4-phenylbutyrate] (HPN-100), based upon the urinary excretion of the drug metabolite


phenylacetylglutamine (PAGN) and/or total urinary nitrogen. It is based in part on the discoveries that bioavailability of these drugs as conventionally assessed based on systemic blood levels of the drugs themselves or of the active species produced *in vivo* from these drugs does not accurately predict removal of waste nitrogen or reduction of plasma ammonia in healthy human volunteers, adults with liver disease, or patients with UCDS receiving ammonia scavenging drugs as defined below and that conversion of orally administered sodium phenylbutyrate (NaPBA, or sodium PBA) to PAGN to urinary PAGN is incomplete, typically about 60-75%. Prodrugs of phenylbutyrate (PBA, the active ingredient in BUPHENYL[®] (sodium phenylbutyrate), which is the sodium salt of PBA along with small amounts of inert ingredients), which is itself a prodrug of phenylacetic acid (PAA), are especially subject to the effects described herein.



[0013] As used herein “ammonia scavenging drugs” is defined to include all orally administered drugs in the class which contain or are metabolized to phenylacetate. Thus, the term includes at least phenylbutyrate, BUPHENYL[®] (sodium phenylbutyrate), AMMONAPS[®], butyryloxymethyl-4-phenylbutyrate, glyceryl tri-[4-phenylbutyrate] (HPN-100), esters, ethers, and acceptable salts, acids and derivatives thereof. These drugs reduce high levels of endogenous ammonia by providing phenylacetic acid *in vivo*, which is metabolized efficiently to form phenylacetyl glutamine (PAGN). PAGN is efficiently excreted in urine, carrying away two equivalents of nitrogen per mole of PAA converted to PAGN. References herein to sodium phenylbutyrate are understood to include reference to the drug product BUPHENYL[®], and BUPHENYL[®] was used for the Examples herein wherever test subjects were treated with sodium

phenylbutyrate. Thus the sodium PBA dosages used in the Examples generally refer to a dosage of BUPHENYL[®], and the amounts of sodium phenylbutyrate in those Examples should be interpreted accordingly. Note that the terms ‘ammonia scavenger’ and ‘nitrogen scavenger’ are used interchangeably in this invention, reflecting the fact that the drugs described herein lower blood ammonia through elimination of waste nitrogen in the form of PAGN.

[0014] In some embodiments, the invention uses prodrugs that can be converted into PAA within the body. Sodium phenylbutyrate (sodium PBA) is one such drug; it is converted by oxidative mechanisms into PAA in the body. HPN-100 is another such drug: it can be hydrolyzed to release PBA, which in turn can be oxidized to form PAA. Thus, HPN-100 is a prodrug of PBA, and also a prodrug of PAA. Clinical evidence demonstrates that HPN-100 is converted into PAA in the body as expected, and that PAA is then linked to a molecule of glutamine and converted into PAGN, which is eliminated in the urine as predicted. This process can be summarized as follows:



[0015] PAGN is mainly excreted in the subject’s urine, and removes two molecules of ammonia per molecule of excreted PAGN. Each HPN-100 molecule forms three PAA molecules, so each molecule of HPN-100 can promote excretion of six molecules of ammonia. The clinical results suggest that conversion of HPN-100 into PBA and PAA is efficient and fairly rapid, but surprisingly suggest that some conversion of HPN to PAGN may occur before the HPN-100 (or PBA, or PAA derived from PBA) enters systemic circulation. As a result, systemic levels of PAA or PBA are not reliably correlated with the efficacy of HPN-100 as an ammonia scavenger.

[0016] In some embodiments, the invention uses a prodrug of PBA, including HPN-100 and other esters of phenylbutyrate. The PBA prodrug is thus a prodrug of a prodrug, since PBA acts to scavenge ammonia after it is converted to PAA and is thus considered a prodrug of PAA. In some embodiments, the PBA prodrug is an ester of phenylbutyrate, such as those described below; a preferred PBA prodrug for use in the invention is HPN-100. These compounds can be made and used by methods disclosed in U.S. Patent No. 5,968,979, which is incorporated herein by reference for its description of these compounds and methods for their administration.


[0017] Where an ‘equal molar’ or ‘equimolar’ amount of a second drug is to be used along with or instead of a certain amount of a first drug, the amount of each drug is calculated on a molar basis, and the equimolar amount of the second drug is the amount that produces an equal molar

amount of active drug *in vivo*. Where one of the drugs is a prodrug, the amount of prodrug will typically refer to the molar amount of the active species formed from that prodrug. That active species is usually PAA for the prodrugs described herein, and the molar amount of a prodrug corresponds to the amount of PAA that would form in the body from that amount of the prodrug, assuming complete conversion into PAA occurs *in vivo*. Thus, for example, a molecule of HPN-100 can be metabolized by ester hydrolysis followed by oxidation to form three molecules of PAA, so a mole of HPN-100 would be considered equimolar to three moles of PAA. Similarly, since HPN-100 hydrolyzes to form three molecules of PBA (and one molecule of glycerin), an equimolar amount of HPN-100 would be one-third of the molar amount of PBA.


[0018] The following Table sets forth amounts of HPN-100 that correspond to equimolar amounts of certain relevant doses of BUPHENYL[®] (sodium phenylbutyrate). Note that the conversion of the dose of sodium PBA to the dose of HPN-100 involves correction for their different chemical forms [i.e. HPN-100 consists of glycerol in ester linkage with 3 molecules of PBA and contains no sodium; (sodium PBA [g] x 0.95 = HPN-100 [g])] as well as correction for the specific gravity of HPN-100, which is 1.1 g/mL.

BUPHENYL [®] (sodium PBA)	HPN-100 PBA Equivalent Dose (mg)	HPN-100 PBA Equivalent Dose (mL)
450-600 mg/kg/day (patients ≤ 20 kg)	428 – 570 mg/kg/day	0.39-0.52 mL/kg/day
9.9-13.0 g/m ² /day (patients > 20 kg)	9.4 – 12.4 g/m ² /day	8.6-11.2 mL/m ² /day
Maximum Daily Dose: 20 g	Maximum Daily Dose: 19 g	17.4 mL

[0019] The present invention can use prodrugs of the formula (I):




wherein R₁, R₂, and R₃ are independently, H,




and n is zero or an even number, m is an even number and at least one of R_1 , R_2 , and R_3 is not H. For each R_1 , R_2 , or R_3 , n or m is independently selected, so the R_1 , R_2 , and R_3 groups in a compound of formula I do not have to be identical. The preferred compounds are those wherein none of R_1 , R_2 , and R_3 is H, and frequently each n or m for a particular embodiment is the same, i.e., R_1 , R_2 , and R_3 are all the same. The advantage over the prior art of decreased dosage is greater with such triesters, and having all three acyl groups the same reduces issues related to mixtures of isomers. Moreover, the triol backbone liberated by hydrolysis of the esters is glycerol, a normal constituent of dietary triglyceride which is non-toxic.

[0020] The present invention also utilizes phenylbutyrate and phenylacetate prodrugs of the formula II:



wherein R is a C_1 - C_{10} alkyl group,

R_4 is




and n is zero or an even number, and m is an even number.

[0021] In Formula II, R can be, for example, ethyl, propyl, isopropyl, n-butyl, and the like.

[0022] The compounds of the invention are esters of the congeners of phenylalkanoic and phenylalkenoic acids having an even number of carbon atoms in the alkanolic acid portion, which include phenylacetic acid esters and those of phenylbutyric acid, etc., which can be converted by efficient beta-oxidation processes to phenylacetic acid in the body. They are thus prodrugs for phenylacetic acid. Where n is 2 or 4, the esters are also prodrugs for phenylbutyric acid. Preferably the alkylene or alkenylene carboxylate group contains 24 or fewer carbon atoms, so n or

m is less than 24. In some embodiments, n and m are 0, 2, 4 or 6, and in some preferred embodiments n or m is 2.

[0023] Certain preferred embodiments of the invention use HPN-100 (Formula III):



[0024] Total daily dosage of prodrugs like sodium PBA can often be selected according to the amount needed to provide an appropriate amount of the active species, if that amount is known or can be determined. PBA is a prodrug for PAA; therefore, an initial dose of PBA could be selected if an effective dosage of PAA were known, taking into account the fraction of PBA that is converted into PAA and ultimately into PAGN. If a subject has been treated with PAA or a prodrug that forms PAA in the body, the amount of the previously used drug that was effective provides a possible starting point for selecting a dosage of a new prodrug of PAA. In this same patient, after the new prodrug is administered at the expected PAA dose equivalence, the PAA levels in the subject could be monitored and the dose of the prodrug adjusted until the same plasma level of PAA that was effective with the previous treatment is achieved. However, the current invention is based in part on finding that plasma PAA and PBA levels are not well correlated with the dose of a PBA prodrug administered or with ammonia elimination; for monitoring a dosing level of a PBA prodrug, one should not rely upon these parameters to assess the effectiveness of the prodrug. While not bound by the underlying theory, explanations for this effect (i.e. the inconsistent relationship between ammonia scavenging and PBA and/or PAA blood levels) are provided herein.

[0025] The following Table provides data from three clinical test groups showing the inconsistent relationship between plasma PAA and PBA levels among healthy volunteers, patients with cirrhosis and UCD patients, despite that fact that, as described in detail below, all groups exhibited similar ammonia scavenging activity based on urinary excretion of PAGN. Overall, this shows that urinary PAGN provides a convenient method for monitoring ammonia elimination induced by the administered drug, which does not require drawing blood and directly relates to the actual nitrogen elimination provided by the administered nitrogen scavenging drug without being influenced by the many other factors that can affect plasma ammonia levels.

Plasma Pharmacokinetics of PBA, PAA, and PAGN Comparison across Studies

Analyte	Treatment	C _{max} (µg/mL)	T _{max} (h)	T _{1/2} (h)	AUC ₂₄ (µg·h/mL)
Healthy Volunteers (Single Dose – 3 g/m²/day PBA Mole Equivalent)					
PBA	Sodium PBA	221.0	0.9	0.7	542.6
	HPN-100	37.0	2.4	1.9	137.2
PAA	Sodium PBA	58.8	3.9	1.2	279.8
	HPN-100	14.9	4.0	NC	70.9
PAGN	Sodium PBA	63.1	3.2	1.7	395.1
	HPN-100	30.2	4.0	NC	262.1
Healthy Volunteers and Cirrhotic Patients (100 mg/kg BID)¹					
PBA	Child-Pugh A	42.8	2.3	1.2	131.7
	Child-Pugh B	41.8	2.9	3.4	189.5
	Child-Pugh C	44.3	3.1	1.9	192.1
	Volunteers	29.8	3.0	2.1	132.7
PAA	Child-Pugh A	33.2	3.8	1.8	168.8
	Child-Pugh B	30.8	4.5	2.8	252.4
	Child-Pugh C	53.1	4.8	7.7	579.9
	Volunteers	25.5	3.6	1.9	130.5
PAGN	Child-Pugh A	37.7	3.9	5.0	335.1
	Child-Pugh B	38.1	4.0	7.5	466.99
	Child-Pugh C	43.1	5.3	4.0	578.4
	Volunteers	46.3	4.3	7.2	550.9
UCD Subjects (Multiple Dose – PBA Mole Equivalent)					
PBA	Sodium PBA	141.0	2.1	NC	739.0
	HPN-100	70.1	6.1	NC	540.0
PAA	Sodium PBA	53.0	8.1	NC	595.6
	HPN-100	40.5	8.0	NC	574.6
PAGN	Sodium PBA	83.3	7.2	3.9	1133.0
	HPN-100	71.9	8.0	4.8	1098.0

C_{max} = maximum plasma concentration; T_{max} = time of maximum plasma concentration; AUC₂₄ = AUC from time 0 to 24 hours; NC = not calculated

¹Study did not include a sodium phenylbutyrate comparator arm, values represent HPN-100 dosing only. AUC values represent the AUC from time 0 to the last measurable plasma concentration.

[0026] One embodiment of the invention is a method for determining and/or adjusting the dose of ammonia scavenging drugs in patients with UCDs, whereby dose would be based on the amount of dietary protein the patient is consuming, the anticipated percentage conversion of the drug to PAGN, and the patient's residual urea synthetic capacity, if any. Dose adjustments, if necessary, would be based on the observed urinary excretion of PAGN and/or total urinary nitrogen (TUN), the difference between the two reflecting the patient's endogenous capacity for waste nitrogen

excretion. This endogenous capacity may be absent in certain patients having innate urea cycle disorders due to inborn metabolic deficiencies, but patients with later-onset nitrogen accumulation disorders generally have some endogenous capacity, referred to sometimes as their residual urea synthesis capacity. See Brusilow, *PROGRESS IN LIVER DISEASES*, Ch. 12, pp. 293-309 (1995). The subject's plasma ammonia level may also be determined; this is a critical parameter for tracking effectiveness of an overall treatment program, but reflects a variety of factors such as dietary protein and physiological stress, as well as the effect of a drug used to promote nitrogen excretion.

[0027] Once the patient's residual endogenous capacity for waste nitrogen excretion has been determined, either as the difference between PAGN output and total nitrogen output or as total urinary nitrogen output in the absence of an ammonia scavenging drug, the tolerable amount of dietary protein can be calculated for that patient according to the dosage of the ammonia scavenging drug being administered, or the dosage of the ammonia scavenging drug can be adjusted or calculated to compensate for an estimated protein intake.

[0028] Another embodiment is a method for determining and adjusting the dose of an ammonia scavenging drug to be administered to a patient with liver disease, including hepatic encephalopathy, whereby the starting dose would be based on the amount of dietary protein the patient is consuming, the anticipated conversion of the drug to PAGN, and the patient's residual urea synthetic capacity, if any. While the urea synthetic capacity in patients with liver disease would generally be greater than for patients with UCDs, considerable patient to patient variability would be expected among both groups depending, respectively, on the severity of their liver disease and the severity of their inherited enzymatic defect. Dose adjustments based on the observed urinary excretion of PAGN and total waste nitrogen would adjust for these individual patient characteristics.

[0029] Another embodiment is a method for determining or adjusting allowable dietary protein in the diet of a patient with UCD or with hepatic encephalopathy, who is being treated with an oral PAA-forming ammonia scavenging drug, whereby the amount of allowable protein would be determined by the amount of PAGN and total nitrogen in the urine. The difference between total waste nitrogen in the urine and the amount of PAGN excreted is indicative of the patient's endogenous waste nitrogen processing capacity. Once the patient's endogenous nitrogen processing capacity is known, the patient's endogenous nitrogen processing capacity can be used to adjust dietary protein intake while administering a fixed dosage of an ammonia scavenging drug, or the dosage of the ammonia scavenging drug can be determined according to the amount needed

to facilitate elimination of the waste nitrogen from the patient's dietary protein. Dietary protein intake should be determined or adjusted according to how much nitrogen the subject can eliminate above the amount that is eliminated as PAGN, which results from the PAA-forming ammonia scavenging drug being administered. When making these calculations or adjustments, it is suitable to assume that about 47% of nitrogen in protein will become waste nitrogen that needs to be excreted in the urine (the amount may be less for growing patients, who retain a greater fraction of ingested nitrogen to support body growth), and that about 16% of protein, on average, is nitrogen (see Brusilow 1991).

[0030] It has generally been assumed for such determinations that a prodrug would be converted with 100% efficiency into PAGN for elimination [see, e.g., Berry et al., *J. Pediatrics* 138(1), S56-S61 (2001) where Figure 1 assumes 100% conversion]; and one report found that about 80-90% of PAA or PBA was excreted from a specific individual as PAGN. Brusilow, *Pediatric Research* 29(2), 147-150 (1991). It has now been found that HPN-100 and phenylbutyrate are both converted into urinary PAGN at an overall efficiency of about 60% to about 75% on average (about 60% conversion efficiency was seen in UCD patients and about 75% conversion was seen in cirrhotic patients, for example); consequently, this efficiency factor can be used to more accurately calculate or determine initial dosing levels for these drugs, or dietary protein levels acceptable for patients who use these drugs. Given this conversion rate, each gram of HPN-100 can facilitate elimination of waste nitrogen from about a gram (~1.3 grams) of dietary protein per day. Note that PAGN carries away two molecules of ammonia per molecule of PAGN. Examples of calculations based on these parameters are provided in Examples 9 and 10 herein.

[0031] In one aspect, the invention provides a method for transitioning a patient from phenylacetate or phenylbutyrate to HPN-100 or other esters or prodrugs of phenylbutyrate. The method involves administering an initial dosage of the prodrug that is selected based on the patient's current dosage of phenylacetate or phenylbutyrate, and is adjusted according to the levels of excreted PAGN that result when the prodrug is administered.

[0032] In some embodiments, the transition from phenylbutyrate might be undertaken in more than a single step and urinary excretion of PAGN and total nitrogen would allow monitoring of ammonia scavenging during the transition (e.g. for clinically 'fragile' patients with a propensity for frequent hyperammonemia). The methods can use two, three, four, five, or more than five steps as judged clinically prudent. At each step, a fraction of the initial dosage of phenylbutyrate corresponding to the number of steps used for the transition is replaced by an appropriate, amount

(i.e. the amount necessary to deliver an equimolar amount of PBA) of HPN-100 or other prodrug of phenylbutyrate, e.g., if the transition is to be done in three steps, about one-third of the phenylbutyrate would be replaced with a prodrug at each step.

[0033] Another embodiment of the invention is based on observations that delivery of PBA in the form of a glyceryl tri-ester or other prodrug imparts slow release characteristics that allow greater flexibility in dosing schedule. Sodium phenylbutyrate (sodium PBA), for example, is typically dosed every 4 to 8 hours, or even more frequently, in order to maintain a suitable plasma level of PAA. This regimen reflects the rapid absorption of phenylbutyrate from the gastrointestinal tract and quick metabolic conversion to PAA. HPN-100, by contrast, which is a glyceryl tri-ester of phenylbutyrate, has been found to be absorbed only 40% as rapidly as sodium PBA, enabling dosing three times daily, such as with meals, or even twice daily, such as morning and evening. This dosing flexibility is further enhanced by the fact that the pharmacokinetic (PK) and pharmacodynamic (PD) properties of HPN-100 are indistinguishable in the fed or fasted states. It is thus not critical for the frequency of administration to be rigidly maintained with the PBA prodrugs in the form of an ester; the number of doses per day can be reduced for greater convenience, and the dosages do not have to be linked to meal schedules as is recommended in the label for sodium PBA. Indeed, pharmacokinetics for utilization of HPN-100 were very similar when HPN-100 was taken with food or without food, after a day of fasting, so HPN-100 can be taken with food or without food. This translates into a more convenient treatment protocol and potentially higher patient compliance upon substituting HPN-100 for phenylbutyrate or phenylacetate. Surprisingly, even though HPN-100 and sodium PBA are both prodrugs of PAA, HPN-100 is effective when administered less frequently than sodium PBA. While it is typically necessary to administer smaller doses of sodium PBA 3-6 times per day to maintain a stable level of plasma ammonia, similar results can be achieved with only 2-3 doses of HPN-100 per day. In some embodiments discussed in greater detail below, HPN-100 is administered in two doses per day (BID), and in some embodiments it is administered in three doses per day (TID).

[0034] It has also been found that because of the slow-release characteristics of HPN-100, a patient taking HPN-100 has more sustained and often lower plasma levels of PBA and PAA than a patient taking sodium PBA itself. This is believed to be consistent with the greater flexibility in dosing that is discussed in more detail elsewhere in this application (plasma levels of PBA rise and fall more quickly after administration of sodium PBA than after administration of HPN-100).

[0035] Other aspects of this invention relate to the observation that there is apparently no saturation in the ability of the body to convert sodium PBA or HPN-100 to urinary PAGN over a several-fold dose range up to and including, the maximum doses of sodium PBA recommended to date. This should enable a patient to take a higher dose of HPN-100 than an equimolar amount compared to the patient's dosage of PBA. It suggests a patient can receive a higher dosage of HPN-100 than those dosages of sodium PBA that have been recommended to date, which is especially useful for patients whose ammonia levels were not adequately controlled by the highest labeled dosages of sodium PBA. Such patients can receive doses of HPN-100 that are higher than previously recommended sodium PBA dosages.

[0036] Other aspects of the invention will be apparent from the following detailed description and the examples provided herein.

[0037] For convenience, the amounts of PAA (phenylacetic acid), PBA (phenyl butyric acid), or HPN-100 to be administered to a subject as discussed herein refer to a total daily dosage. Because these compounds are used in relatively large daily amounts, the total daily dosage may be taken in two, three, four, five, or six, or more than six daily doses, and different drugs may be administered on different schedules. Thus the total daily dosage better describes a treatment regimen with one drug for comparison to treatments with related drugs.

Brief Description of the Drawings

[0038] Figure 1 shows waste nitrogen disposal via the urea cycle and by the auxiliary pathway involving PAGN.

[0039] Figure 2 depicts a conventional model to describe pharmacokinetic (PK) behavior of a prodrug, which, in the case of phenylbutyrate, assumes that PBA and PAA must reach the systemic circulation in order to be active; i.e., in order to be converted to PAGN and effect ammonia scavenging.

[0040] Figure 3 depicts an adapted model to describe PK behavior of sodium PBA or other drugs such as HPN-100 that can be converted to PBA and PAA, informed by the observations described herein showing that metabolism of HPN-100 results in lower plasma levels of PAA and PBA while providing equivalent pharmacological effect. Unlike the conventional model, this model allows for 'pre-systemic' conversion of PBA/PAA to PAGN and explains inconsistent relationship between blood levels of these metabolites and PAGN-mediated excretion of waste nitrogen

[0041] Figure 4 shows how plasma levels of PAA, PBA, and PAGN change over time following administration of a single dose of either PBA or HPN-100. It shows that the peak level of PAA is lower when the PBA prodrug, HPN-100, is used, and the PAA level at 24 hours post-administration is higher with the prodrug. Thus the prodrug provides a more sustained level of plasma PAA.

[0042] Figure 5 presents data on ammonia levels from the tests in Example 3.

[0043] Figure 6 presents an anatomic explanation for the observations that the prodrug (PBA) can be converted to PAGN prior to reaching the systemic circulation (corresponds to the model depicted in Figure 3).

[0044] Figure 7 shows that PBA levels fluctuate relatively rapidly after dosing in healthy adults, while PAA and PAGN levels reach a fairly stable state after a few days of treatment with sodium phenylbutyrate.

[0045] Figure 8 shows that PBA, PAA and PAGN levels reach steady states at different times in healthy adults and that PAA takes longer to reach a steady state level in cirrhotics

[0046] Figures 9a, 9b, and 9c show that in subjects treated with HPN-100, there is little or no correlation between the dose of HPN-100 and plasma levels of either PBA or PAA in the subject. However, it also shows that urinary excretion of PAGN correlates well with dosage of HPN-100.

[0047] Figure 10 shows plasma ammonia levels [time-normalized area under the curve, or TN-AUC or Area under the curve (AUC)] during the day and night for 10 UCD patients treated for seven days with either sodium PBA or an equimolar dosage of HPN-100, and illustrates that HPN-100 provided better control of ammonia levels than PBA: both the AUC (area under the curve), which is an index of total ammonia exposure, and C_{max}, which measures the peak concentration of ammonia, were lower in subjects receiving HPN-100 than in subjects receiving an equimolar dosage of PBA.

[0048] Figure 11 shows that HPN-100 did a better job than PBA of managing plasma levels of nitrogen overnight.

[0049] Figure 12 demonstrates that in patients whose ammonia levels were well controlled on sodium PBA, HPN-100 maintained control. By contrast, patients whose ammonia levels were elevated despite treatment with sodium PBA exhibited the greatest benefit in terms of improved ammonia control from HPN-100.

[0050] Figure 13 summarizes the data from Figure 12 and provides a statistical comparison of ammonia levels for patients on sodium PBA and those on HPN-100. It also shows the normal range for each set of patients.

Modes of Carrying Out the Invention

[0051] In one aspect, the invention is reduced to practice in determining the dose, dosing schedule and dose adjustments necessary for treatment of nitrogen retention states including urea cycle disorders and liver disease complicated by hepatic encephalopathy. The starting dose and schedule would be based upon the theoretical considerations including the estimated percentage conversion of the drug to PAGN, the waste nitrogen resulting from the patient's dietary protein and the percentage of drug converted to and excreted as PAGN. Following initiation of treatment, further dose adjustments would then be made if necessary, upon the actual measurement of urinary PAGN output, or a well-correlated parameter like total urinary ammonia or the ratio of PAGN to creatinine.

[0052] In another aspect, the invention provides a method to transition a patient from phenylbutyrate or phenylacetate to a prodrug of phenylbutyrate (which is a prodrug of PAA), such as HPN-100, or other ester or prodrugs such as compounds of Formula I and II as shown herein. For a number of reasons, HPN-100 is considered a more desirable drug than sodium PBA for many patients who have high ammonia levels and require treatment with an ammonia scavenging drug. In particular, it avoids the unpleasant taste associated with sodium PBA, and it reduces potentially harmful sodium intake, since phenylbutyrate is administered as a sodium salt. A large majority of patients (nine out of ten UCD patients who participated in the clinical study described in example 3) preferred HPN-100 over sodium PBA in clinical testing. Thus many patients who have been treated with phenylbutyrate as an ammonia scavenging drug may want to transition from it to HPN-100.

[0053] It would seem logical for a physician to transition a patient from phenylbutyrate to a prodrug of phenylbutyrate by calculating the amount of the prodrug that would produce an amount of PBA that corresponds to the dosage of phenylbutyrate previously administered to the patient. This would be expected to produce about the same blood plasma level of the active ingredient, PBA. Efficacy of the new treatment with the prodrug could then be assessed by monitoring levels of phenylbutyrate in the blood, to establish the same levels achieved when PBA was administered. As discussed below, however, that approach is not appropriate because, surprisingly, plasma levels of PBA do not correlate well with administered dosages of HPN-100 or with the effectiveness of a

dose of HPN-100 or sodium PBA. (Note that sodium PBA is the acid form of phenylbutyrate, which is the common name for the drug BUPHENYL[®], and is typically administered as BUPHENYL[®], which is a sodium salt of PBA. References to treatment with PBA herein encompass administration of the phenylbutyrate neutral compound or a salt of phenylbutyrate. Typically, and in all of the working examples herein, PBA is administered as BUPHENYL[®].)

[0054] Alternatively, since PBA is a prodrug for PAA, the dosage of a phenylbutyrate prodrug could be calculated according to the theoretically formed amount of PAA, which should be the same amount as what would be calculated from the PBA dosage, since one molecule of PBA is expected to produce one molecule of PAA. The molecular weight of sodium PBA, the registered drug form of PBA (the sodium salt of PBA), is 186; the molecular weight of HPN-100 is 530, and of course HPN-100 provides three equivalents of PBA per molecule, so only one-third as many moles of HPN-100 would be needed to replace a molar quantity of either PBA or PAA. Thus each gram of sodium PBA could be replaced by 0.95 grams of HPN-100; and since HPN-100 is a liquid having a density of 1.1 g/mL, each gram of sodium PBA would be replaced by 0.87 mL of HPN-100, assuming HPN-100 is used as an undiluted liquid. This can be used to select a starting dosage of HPN-100 for patients being transitioned from sodium PBA to HPN-100. Alternatively, a starting dose of HPN-100 in a patient not already taking BUPHENYL[®] (sodium phenylbutyrate) would need to take into account the surprising observation described in more detail below (see examples 2 and 3) that conversion of the PBA, when administered as HPN-100, into urinary PAGN is incomplete and averages about 60-75%.

[0055] Alternatively, the physician could measure plasma levels of either PBA or PAA in a subject receiving an effective amount of PBA, and determine a dosage of a PBA prodrug by administering enough of the prodrug to produce the same plasma levels of PBA or PAA. The physician could then monitor the amount of either PBA or PAA in the blood to ensure that the appropriate amount of active drug was being produced in the body. It might be expected that a prodrug of phenylbutyrate would provide a slightly lower blood plasma concentration of PAA or PBA than phenylbutyrate, and thus a lower nitrogen-scavenging effect, since conversion of the prodrug to the active drug might be less than 100% efficient. Thus monitoring PAA or PBA plasma levels and increasing the prodrug dosage to bring levels up to those obtained by administering phenylbutyrate might be expected to produce the same physiological effect as the phenylbutyrate dosage. However, it was found that it is not necessary for the plasma level of PAA or PBA observed upon administration of a prodrug of phenylbutyrate to match that produced by an

effective amount of phenylbutyrate, in order to achieve the same ammonia-scavenging effect. Rather, efficacy of the prodrug HPN-100 correlates with urinary PAGN levels, not with plasma levels of PAA or PBA.

[0056] Models have been developed to describe how ammonia-scavenging drugs or prodrugs are expected to behave *in vivo*. One model, shown in Figure 2, reflects conventional approaches to assessing drug effectiveness as applied to HPN-100 based on blood levels of PAA or PBA. Clinical testing has shown that HPN-100 does not produce the plasma levels of PAA and PBA that might be expected from this model, though, even though it is at least as effective on an equimolar basis as PBA for controlling blood ammonia levels, and for eliminating ammonia as PAGN via the urine. Thus the conventional model fails to account for some important metabolic differences between PBA and HPN-100. It was hypothesized that, as compared with sodium PBA, a greater percentage of PBA derived from HPN-100 is converted into PAGN for elimination (or PAA or PBA derived from it) before entering the systemic circulation (the “central compartment” in Figure 2). Recognition of this important and unexpected difference underlies certain aspects of the present invention.

[0057] A refined working model based upon the observations described herein and as outlined in this disclosure is depicted in Figure 3. It supports the conclusion that PBA derived from HPN-100 as well as from sodium PBA can be converted into PAGN without entering into systemic circulation; presumably, HPN-100 or its initial metabolic products (*e.g.*, a compound of formula I wherein one or two of R₁-R₃ represent phenylbutyryl groups, and the remaining one or two of R₁-R₃ represent H—the expected products of partial hydrolysis of HPN-100) may reach the liver and be converted into PAGN there, prior to reaching the systemic circulation. Moreover, the fractional conversion of PBA derived from HPN-100 is greater than for PBA absorbed when PBA is administered as the salt, an observation which explains the lower blood levels of PBA following administration of HPN-100 as compared with sodium PBA despite equivalent or potentially superior ammonia scavenging activity. This observation led to the recognition that plasma levels of PAA or PBA are not reliable indicators of the effectiveness of a PBA prodrug like HPN-100, and should not be relied upon to set or adjust dosages of such PBA prodrug compounds. Data presented herein, *e.g.* as summarized in Figure 9, demonstrate this effect. Alternative methods for monitoring a subject treated with HPN-100 are needed, and are provided herein.

[0058] In addition, PK/PD modeling, as reflected by considerations and depicted in figures 3 and 6, demonstrate that HPN-100 is absorbed only about 40% as rapidly as PBA when dosed

orally. As a result, HPN-100 provides a slow-release delivery effect, even though it appears to metabolize to PBA rapidly once absorbed. This provides greatly flexibility in dosing and explains why HPN-100 can be dosed, e.g., three times per day or even twice per day to provide similarly stable ammonia levels that require four or more doses of PBA to achieve.

[0059] In view of these observations of unexpected pharmacokinetic behavior, plasma PAA and PBA levels should not be used to evaluate or monitor treatment of a subject with HPN-100 or sodium PBA. Alternative methods are needed, and are provided herein, for monitoring a subject treated with HPN-100. For one, it has been found that between 50 and 85% of HPN-100 is converted into urinary PAGN, typically about 60% to about 75%. This conversion efficiency for HPN-100 and sodium PBA in UCD patients is surprising in light of previous references that have generally assumed the conversion efficiency of sodium PBA to be about 100%. Urinary PAGN has been shown to be inversely correlated with levels of waste nitrogen, e.g. ammonia, in the blood, thus efficacy of HPN-100 can be evaluated by measuring urinary PAGN. It has also been found that HPN-100 has little to no effect on creatinine levels. Moreover, because creatinine levels in healthy adults and patients with nitrogen retention states are typically rather stable, either measuring PAGN output in urine over time, or measuring the ratio of the concentrations of PAGN to creatinine, which can be conveniently done in spot testing, provides a way to monitor HPN-100's effectiveness. In one aspect, the invention thus provides a method to assess the effectiveness of a treatment with HPN-100, comprising determining the ratio of PAGN to creatinine in a 'spot urine' test. Clinical studies show that urinary excretion of PAGN, and the ratio of PAGN to creatinine in urine, correlate well with blood ammonia levels: an increase of PAGN or of the PAGN / creatinine ratio correlates with decreasing plasma ammonia levels. Accordingly, in one method, HPN-100 treated patients are monitored by measuring urinary PAGN output, or by measuring the ratio of PAGN to creatinine in spot urine testing. This method can be used to monitor treatment of a treatment-naïve patient, or of a patient being transitioned from PBA to HPN-100, or a patient being treated with HPN-100. Increasing levels of urinary PAGN output, or an increase in the ratio of PAGN to creatinine in spot testing provides a way to determine whether a dosing regimen that utilizes HPN-100 or another PBA prodrug is promoting elimination of excess ammonia, and to compare two treatment methods to determine which is more effective for the particular subject.

[0060] While plasma ammonia levels are often used to assess disease control in UCD patients, it is often inconvenient to rely upon plasma ammonia levels for optimizing the dosing of HPN-100

outside of a clinical setting. Moreover, plasma ammonia levels are affected by many factors and might be elevated regardless of how well a drug treatment works; it reflects dietary and other factors as well as the adequacy of a drug dosage being used. Plasma ammonia varies a good deal even when relatively well-controlled, based on meal timing, drug timing, and various other factors. Thus to meaningfully reflect drug effect, the plasma ammonia levels need to be monitored over time by repeated blood samplings, which is not practical for routine monitoring of some patients and which does not provide direct information about whether an ammonia scavenging drug is working. Measurements of urinary PAGN, on the other hand, can be done more conveniently as a routine monitoring method because they do not require medical assistance to collect the samples for testing. Moreover, urinary PAGN specifically measures the waste nitrogen clearance provided by the scavenging agent, while many other factors affecting ammonia levels may cause ammonia control to be misleading with regard to the actual effect of the nitrogen scavenging drug. Thus, even though in theory a number of different parameters could be measured to assess effectiveness of a dosage of HPN-100, only measurements based on urinary PAGN are both convenient and reliable as a direct measurement of the nitrogen scavenging drug's effect.

[0061] Thus in one embodiment, the invention provides a method to monitor the effectiveness of treatment of a UCD patient with HPN-100, where monitoring consists essentially of monitoring the patient's urinary PAGN excretion, and optionally checking plasma ammonia levels. Urinary PAGN levels comparable to those achieved with a previous PBA dosing regimen would be considered evidence that the HPN-100 treatment was equally effective as the PBA treatment it replaced. Alternatively, a plasma ammonia level of less than about 40 $\mu\text{mol/L}$, or of not greater than 35 $\mu\text{mol/L}$ would indicate the treatment was effective. In some embodiments, rather than using urinary PAGN output measured over time, one can use the ratio of PAGN to creatinine in the urine, in a spot test.

[0062] In another aspect, the invention provides a utilization efficiency factor for HPN-100 or for sodium PBA of about 60% to about 75%, which can be used to more accurately determine an initial starting dose of either drug and/or correlate dietary protein intake with projected urinary PAGN.

[0063] In one aspect, the invention provides a method for transitioning a patient from phenylbutyrate to HPN-100 or other esters or prodrugs of phenylbutyrate. The method involves administering an initial dosage of the prodrug that is selected based on the patient's current dosage of phenylbutyrate. For example, the amount of HPN-100 needed to provide an equal molar

amount of PBA would be calculated (an equimolar amount), and this equimolar amount would be administered to the patient. Urinary excretion of PAGN or plasma ammonia levels would be monitored, and the dosage of HPN would be increased or decreased as needed to establish a level of PAGN excretion that is about the same as that provided by a previously used effective amount of phenylbutyrate or another nitrogen scavenging drug. Typically, a subject being transitioned from PAA or another PAA prodrug onto HPN-100 using this method would be tested for urinary PAGN output prior to the transition and afterwards, and the dosage of HPN-100 would be adjusted as needed to match the urinary PAGN output from this patient when treated with the previous PAA drug or prodrug, assuming the previous PAA prodrug treatment was considered effective. This provides a safer and more effective transition to the new prodrug than methods that rely upon using an equimolar amount without monitoring the *in vivo* effects of that amount of the new drug. It also avoids the risk of inaccurate dosing and potential overtreatment that could result if one monitored PAA or PBA and tried to adjust the prodrug (i.e. HPN-100) dosage to match the PAA or PBA level to the corresponding level provided by administering sodium phenylbutyrate itself.

[0064] In some embodiments, the transition from phenylbutyrate might be undertaken in more than a single step and urinary excretion of PAGN and total nitrogen would allow monitoring of ammonia scavenging during the transition. In some embodiments, a patient taking an initial dosage of phenylbutyrate is transitioned from phenylbutyrate to a prodrug of phenylbutyrate in steps. The methods can use two, three, four, five, or more than five steps. At each step, a fraction of the initial dosage of phenylbutyrate corresponding to the number of steps used for the transition is replaced by an appropriate amount of HPN-100 or other prodrug of phenylbutyrate. The appropriate amount for each step can be approximately an amount sufficient to provide an equal molar amount of PBA if it is assumed that the prodrug is quantitatively converted into PBA. Note, too, that BUPHENYL[®] (sodium phenylbutyrate) contains about 6% inactive ingredients, so it is appropriate to base calculations upon the PBA content of the drug rather than on the weight of the formulated drug. The patient is then monitored to determine how much ammonia scavenging effect has been provided. The amount of HPN-100 (or prodrug) can then be adjusted to produce about the same amount of ammonia excretion in the form of excreted PAGN that was achieved by the initial dosage of phenylbutyrate, if the patient was well controlled.

[0065] A physician who is switching a patient from PBA to HPN-100 or another ester of phenylbutyrate should be aware that an effective amount of HPN-100 does not necessarily produce a PAA or PBA level that is as high as those seen when sodium phenylbutyrate is administered. It

is reported that PAA exhibits some toxicity at high plasma concentrations. Thibault, et al., *Cancer Research*, 54(7):1690-94 (1994) and *Cancer*, 75(12):2932-38 (1005). Given this, and given the unique properties of HPN-100 described above, it is particularly important that a physician not use plasma levels of PAA or PBA to measure the efficacy of HPN-100. If one administers HPN-100 in amounts sufficient to match the plasma PBA or PAA levels provided by administering phenylbutyrate, for example, the dose of HPN-100 may be unnecessarily high.

[0066] The treatment-naïve patient is one not presently receiving an ammonia-scavenging drug treatment to manage nitrogen levels. While there are recommended dosage levels for the nitrogen scavenging drugs in many cases, the right dosage for a naïve patient may be lower than those ranges, for example, and, less commonly, it may be above an equimolar amount when compared to the dosages recommended for sodium PBA. The initial dosage of PAA or a PAA prodrug can be calculated by methods known in the art once a patient's dietary intake of protein is known, and assuming the patient has a relatively normal liver function. Saul W Brusilow, "Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion," *Pediatric Research* 29:147-150, (1991). Methods are also known for measuring the total amount of nitrogen excreted in the urine; in the case of a subject taking a drug that acts by providing PAA, the total waste nitrogen will include PAGN excreted.

[0067] It is estimated that about 47% of nitrogen in proteins consumed will be converted into waste nitrogen, and that about 16% of protein on average is nitrogen. Using these figures, and assuming HPN-100 is efficiently converted to PAGN, a daily dosage of about 19 g of HPN-100 would provide a vehicle to excrete the waste nitrogen from about 43 g of dietary protein; each gram of HPN-100 would thus be able to carry away waste nitrogen from about 2 g of dietary protein. In addition, if it is estimated that HPN-100 utilization efficiency is between about 50% and 85% in various individual patients (as disclosed herein, it has been found that about 60-75% of HPN-100 is converted into urinary PAGN on average), which is consistent with clinical observations to date, and these factors can be used to further refine the relationship between dietary protein intake and HPN-100 dosing levels for a given subject. With this refinement, each gram of HPN-100 would assist with removal of waste nitrogen for about 1 gram (~ 1.3 grams) of dietary protein. This factor can be used to calculate a suitable dosage of HPN-100 if dietary protein intake is known or controlled, and it can be used to calculate a tolerable dietary protein intake for subject receiving HPN-100.

[0068] This method can also be used to establish a recommended daily dietary protein intake for a patient, by determining the patient's endogenous nitrogen elimination capacity, calculating an amount of dietary protein that this endogenous capacity permits the patient to process without assistance from a nitrogen scavenging drug, and adding to the amount of dietary protein the patient can process on his/her own an amount of protein that the patient would be able to process when using a particular dosage of PBA or a PBA prodrug like HPN-100. Using HPN-100 as an example, a maximum daily dosage of about 19 grams of HPN-100, utilized at an estimated efficiency of 60%, would enable the treated patient to eliminate waste nitrogen corresponding to about 40 g of dietary protein. Thus the invention provides a method to establish a suitable dietary protein level for a patient having a urea cycle disorder or HE, by adding this amount of protein to the amount the patient's endogenous nitrogen elimination capacity can handle.

[0069] In some embodiments, it is also useful to measure PAGN excretion, which accounts for some of the total waste nitrogen excreted when PAA or a PAA prodrug is working. The total waste nitrogen excreted minus the amount of PAGN excreted represents the patient's endogenous capacity for excreting nitrogen wastes via the urea cycle or other mechanisms, and is helpful in determining how much protein intake the patient can manage at a given drug dosage, and also for understanding whether the patient requires extremely close monitoring. The endogenous capacity to excrete nitrogen wastes will be very patient-specific. Dosage of HPN-100 can then be established by determining the subject's endogenous capacity to eliminate waste nitrogen; subtracting the amount of dietary protein corresponding to the subject's endogenous nitrogen elimination capacity; and providing a dosage of HPN-100 sufficient to permit the subject to handle the balance of waste nitrogen, based on the subject's dietary protein intake.

[0070] The plasma or blood level of ammonia is optionally also determined, in addition to measuring urinary PAGN, to assess the effectiveness of the overall drug and dietary regimen for a particular patient. If the ammonia control is inadequate, the dosage of the nitrogen scavenging drug may need to be increased if that can be done, or the patient's dietary protein intake can be decreased if that is feasible.

[0071] In some instances, the dosage of HPN-100 may be limited to dosages that do not exceed recommended dosing levels for phenylbutyrate, adjusting for the fact that each mole of HPN-100 can produce three moles of phenylbutyrate. The label for the use of sodium PBA for the chronic treatment of UCDs recommends a daily dosage not to exceed 20 g; a daily dosage in a range of 9.9-13.0 g/m² set according to the subject's size for subjects over 20 kg in weight; and a dosage

within a range of 450-600 mg/kg for subjects weighing less than or equal to 20 kg is indicated. While lower doses of HPN-100 may provide comparable ammonia scavenging to PBA on a molar equivalent basis, it may be suitable to select a higher dosage of HPN-100 to achieve adequate ammonia control for certain subjects. Typically, that dose will not exceed the recommended ranges for dosages of phenylbutyrate for a given indication. Thus it may be appropriate to administer HPN-100 at a daily dosage not to exceed an amount of HPN-100 that corresponds to the molar amounts of phenylbutyrate described above (and correcting for the fact that HPN-100 can provide three molecules of PBA). For a subject weighing more than 20 kg, a dosage range for HPN-100 would be between 8.6 and 11.2 mL/m². For a subject weighing less than 20 kg, a dosage range of about 390 to 520 µL/kg per day of HPN-100 would be appropriate, based on the use of an equimolar amount compared to the recommended doses of HPN-100. There is no evidence to suggest that HPN-100 would produce adverse effects at a rate in excess of that from an equimolar amount of sodium PBA, so the daily recommended upper limit of 20 g per day of sodium PBA suggests that a daily dose limit of HPN-100 based on the recommendations for sodium PBA would correspond to an equimolar amount of HPN-100, or about 19 g or 17.4 mL.

[0072] Thus in one embodiment, the invention provides a method to monitor the effectiveness of a treatment of a UCD patient with HPN-100, where monitoring consists of, or consists essentially of, monitoring the patient's urinary PAGN excretion and/or plasma ammonia levels. Urinary PAGN levels comparable to those achieved with a previous PBA dosing regimen would be considered evidence that the HPN-100 treatment was equally effective as the PBA treatment it replaced. Alternatively, a plasma ammonia level that was normal, e.g., a level of less than about 40 µmol/L, or of not greater than 35 µmol/L, would indicate the treatment was effective. In some embodiments, rather than using urinary PAGN output measured over time, one can use the ratio of PAGN to creatinine in the urine, in a spot test.

[0073] However, it has also been found that HPN-100 exhibits no indications of toxicity at equimolar doses when compared to the approved PBA dosage of 20 g / day and a dose 2-3 times the equivalent of 20 grams of PBA is unlikely to produce PAA blood levels leading to AEs. Moreover, tolerability of taking HPN-100 is much higher than for PBA and a linear relationship has been observed between HPN-100 dose and PAGN output up to doses of 17.4 mL. In some patients or clinical settings, HPN-100 doses well above the approved PBA dosage are expected to be beneficial; for example, in UCD patients who exhibit recurrent hyperammonemia even on

maximal doses of sodium PBA, in UCD patients who need increased dietary protein to support body requirement, or in patients with other nitrogen retaining states.

[0074] Thus in another embodiment, the invention provides methods to treat a subject having HE or UCD, with a dosage of HPN-100 that corresponds to between 100 and 300% of the equimolar amount of the recommended highest dose of PBA. In some embodiments, the suitable dosage will be between about 120% and 180% of the highest recommended dose of PBA; in other embodiments it will be between 120-140% or from 140-160% or from 160-180% of the equimolar amount of the recommended highest dosage of PBA. In accordance with this aspect, the daily dosage of HPN-100 could be as much as 57 g, or up to about 38 g, or up to about 33 g, or up to about 30g, or up to about 25g.

[0075] In one aspect, the invention provides a method to identify the starting dose or dose range and to individually adjust the dose or dose range of a nitrogen scavenging drug comprising PAA or a PAA prodrug (including HPN-100) used for the management of a treatment-naïve patient, which method comprises the steps of:

- a) administering an initial dosage of the drug estimated according to the patient's dietary protein load, taking into account the expected percentage conversion to PAGN
- b) measuring the amount of total waste nitrogen excreted following administration of the nitrogen scavenging drug comprising PAA or a PAA prodrug;
- c) measuring blood ammonia to determine if the increase in urinary excretion of total waste nitrogen is sufficient to control blood ammonia levels; and
- d) adjusting the initial dosage to provide an adjusted dosage of the nitrogen scavenging drug comprising PAA or a PAA prodrug based upon ammonia control, dietary protein, and the amount of total waste nitrogen excreted by the patient, or the amount of waste PAGN excreted. Either or each of these parameters can be monitored to assess the dosage of HPN-100 or other nitrogen scavenging drug being administered. Optionally, the method also includes determining the subject's endogenous nitrogen eliminating capacity (residual urea synthesis capacity) to further help determine an initial dose of HPN-100.

[0076] The initial dosage of the HPN-100 for a treatment naïve patient can be calculated as the amount of waste nitrogen that needs to be eliminated based on the patient's dietary protein intake. This amount can be reduced by an amount equivalent to the waste nitrogen the patient can eliminate using the patient's endogenous waste nitrogen elimination capacity, which can be measured as described herein. The suitable starting dose of HPN-100 can be calculated by

estimating dietary protein intake that needs to be managed via the nitrogen scavenging drug, and providing a dose of drug amounting to about 1 g of HPN-100 per 1-2 grams of dietary protein in excess of the amount the patient's endogenous nitrogen elimination capacity can handle, taking into account the expected percentage conversion of the administered PBA to urinary PAGN. The method optionally further includes assessing urinary PAGN output to see if it accounts for the expected amount of waste nitrogen, and optionally may include measuring plasma levels of ammonia in the subject to ensure that an acceptable level of ammonia has been achieved. Checking the patient's plasma ammonia levels provides a measure of the effectiveness of the overall treatment program, including diet and drug dosing.

[0077] The table below summarizes the amount of dietary protein that doses of HPN-100 below (dose 1), within (dose 2) and above (dose 3) those corresponding to the recommended dosages of sodium PBA would be expected to 'cover' (i.e. mediate resulting waste nitrogen excretion), given the following assumptions: 1 gram of PAA mediates the excretion of ~0.18 grams of waste nitrogen if completely converted to PAGN; 60% of the PAA delivered as the PBA prodrug released from HPN-100 is converted to PAGN; 47% of dietary protein is excreted as waste nitrogen, and 16% of dietary protein consists of nitrogen (Brusilow 1991; Calloway 1971). These factors can be used when relating dietary protein intake, drug dosing and waste nitrogen elimination for purposes of the present invention.

HPN-100 Doses and Expected Waste Nitrogen Excretion Based on Dietary Protein

Dose 1	3 mL BID	Corresponds to ~0.47x the dose administered in Example 2, for a 70 kg adult and ~0.35x the amount of PBA (~6.1 g) delivered in the maximum approved dose of sodium PBA of 20 g Expected to mediate excretion of waste nitrogen associated with ~8.5 g of dietary protein
Dose 2	9 mL BID	Corresponds to ~1.42x the dose administered in Example 2, for a 70 kg adult and ~0.11x the amount of PBA (~18.2 g) delivered in the maximum approved dose of sodium PBA of 20 g Expected to mediate excretion of waste nitrogen associated with ~26 g of dietary protein
Dose 3	15 mL BID	Corresponds to ~2.36x the dose administered in Example 2, for a 70 kg adult and ~1.73 x the amount of PBA (~30.3 g) delivered in the maximum approved dose of sodium PBA of 20 g Expected to mediate excretion of waste nitrogen associated with ~43 g of dietary protein

[0078] As used herein, plasma levels of ammonia are acceptable when they are at or below a level considered normal for the subject, and commonly this would mean plasma ammonia level is below about 40 $\mu\text{mol/L}$. In certain clinical tests described herein the upper limit of normal for the subjects was between 26 and 35 $\mu\text{mol/L}$, and it is recognized in the art that a normal ammonia level will vary depending upon exactly how it is measured; thus as used to describe ammonia levels herein, 'about' means the value is approximate, and typically is within $\pm 10\%$ of the stated numeric value.

[0079] In other aspects, the invention provides a method to identify a suitable starting dose or dose range for a UCD or HE patient and to individually adjust the dose or dose range of a new nitrogen scavenging drug used for the management of a patient already treated with a previous nitrogen scavenging drug, which method comprises the steps of:

- a) administering an initial dosage of the new nitrogen scavenging drug (which can be estimated according to the patient's dietary protein load and/or the dose of the new drug expected to yield the same amount of urinary PAGN excretion as a previously used nitrogen scavenging drug);
- b) measuring the amount of total waste nitrogen and/or of PAGN excreted following administration of the new drug;
- c) optionally measuring blood ammonia to determine if the initial dosage is sufficient to control blood ammonia levels, or to establish a suitable average ammonia level; and
- d) adjusting the initial dosage of the new drug as needed to provide an adjusted dosage based upon ammonia control, dietary protein, and the amount of total waste nitrogen excreted by the patient. The adjusting of the initial dosage is done based on the amount of urinary PAGN, without relying upon plasma levels of PAA, PBA, or PAGN, and preferably without relying upon plasma levels of ammonia.

[0080] Where the patient has previously been treated with PAA or a PAA prodrug, the treating physician may rely, wholly or in part, upon the previous treatment to set a dosage for a new PAA prodrug, or a PBA prodrug, to be administered to the same patient. If the previous drug was reasonably effective for managing the patient's condition, the physician may set the dosage for a new PAA or PBA prodrug by reference to the previous one, so that the new drug is administered at a dosage that provides the same dosage of PAA to the patient, assuming complete conversion of each prodrug into PAA.

[0081] Again, as discussed above, it is sometimes desirable to measure PAGN excreted in addition to total waste nitrogen excreted. The total waste nitrogen excreted minus the amount of PAGN excreted represents the patient's endogenous capacity for excreting nitrogen wastes via urea cycle or other mechanisms, and is helpful in determining how much protein intake the patient can manage at a given drug dosage, and also for understanding whether the patient requires extremely close monitoring. The endogenous capacity to excrete nitrogen wastes will be very patient-specific.

[0082] In another aspect, the invention provides a method to identify the amount of dietary protein that could be safely ingested by a subject with a nitrogen accumulation disorder, including hepatic encephalopathy and UCD, where the patient is taking an ammonia-scavenging drug that comprises PAA or a PAA prodrug, which method comprises the steps of:

- a) measuring the amount of total waste nitrogen excreted following administration of the drug,
- b) determining the amount of dietary protein calculated to yield an amount of waste nitrogen less than or equal to urinary waste nitrogen; and
- c) adjusting dietary protein and/or drug dosage as appropriate based upon measurement of blood ammonia and total waste nitrogen excretion.

[0083] Where the subject is receiving treatment with a nitrogen-scavenging drug, it may be necessary to reassess the patient's dietary intake of protein periodically, since many factors will affect the balance between nitrogen intake, nitrogen excretion, and dosage of a nitrogen scavenging drug. The invention provides methods to determine how much dietary protein a patient can handle, based on measuring the patient's nitrogen excretion levels. It may further be useful to measure the patient's PAGN level as discussed above, to help determine the patient's endogenous capacity for excreting nitrogen wastes via urea cycle or other mechanisms.

[0084] In the above methods, the patient may be one having a urea cycle disorder, or other nitrogen accumulation disorders. In many embodiments, the methods are applicable to patient's having a urea cycle disorder, but relatively normal liver function.

[0085] The above methods can be practiced with a variety of prodrugs of PAA or PBA. In some embodiments, HPN-100 is the PBA prodrug of choice for these methods.

[0086] In another aspect, the invention provides a method to transition a patient from treatment with an initial amount of phenylacetate or phenylbutyrate to a final amount of a PBA prodrug, comprising:

- a) determining a replacement amount of a PBA prodrug to replace at least a portion of the phenylacetate or phenylbutyrate;
- b) substituting the replacement amount of the prodrug for the portion of phenylacetate or phenylbutyrate; and
- c) monitoring the amount of PAGN excreted by the patient to assess the effectiveness of the replacement amount of the prodrug.

[0087] Optionally, this method comprises adjusting the amount of the prodrug and administering an adjusted amount of the prodrug, then further monitoring PAGN excretion to assess the effectiveness of the adjusted amount of the prodrug. The replacement amount of the PBA prodrug can be about an equimolar amount to the amount of PBA being replaced.

[0088] For reasons discussed extensively herein, it is misleading to rely upon PAA levels when moving a patient to a prodrug (or a new prodrug) of PAA or PBA. The availability of liver-based mechanisms for rapid conversion of a prodrug into PAGN without necessarily entering the systemic system renders plasma levels of PAA and PBA insufficient as predictors of efficacy, so the method relies upon the excreted PAGN for assessing and monitoring treatment with a PAA or PBA prodrug that is to be given to the patient.

[0089] In many cases, it will be possible to transition a patient directly from, e.g., phenylbutyrate to HPN-100 or another PBA prodrug in a single stage, rather than in incremental steps. Thus all of the previously used PAA or PAA prodrug may be replaced with a suitable substitution amount of the new drug (PBA prodrug). However, in some situations (e.g. 'fragile patients', patients taking dosages at or near the recommended limits of PAA or PAA prodrug, and for patients having very limited endogenous capacity for excreting nitrogen wastes, or in situations where the ability of the patient to metabolize or excrete the drug is uncertain), it may be preferable to transition from the initial drug to a new PBA prodrug like HPN-100 in two or more stages or steps. Thus the transition may be made in 2, 3, 4 or 5 steps, and at each step a fraction of the original drug (e.g. about half for a two-step transition, about a third for a three-step transition, etc.) is replaced by the new PBA prodrug to be administered. This approach might be appropriate for a

'fragile' UCD patient known to be susceptible to repeated episodes of hyperammonemia while receiving treatment or while taking a large amount of drug that promotes nitrogen elimination.

[0090] Thus in another aspect, the invention provides a method to transition a UCD patient from treatment with an initial amount of phenylacetate or phenylbutyrate to a final amount of a PBA prodrug, comprising:

- a) determining a replacement amount of a PBA prodrug to replace at least a portion of the phenylacetate or phenylbutyrate;
- b) substituting the replacement amount of the prodrug for the phenylacetate or phenylbutyrate; and
- c) monitoring plasma level of ammonia in the patient to assess the effectiveness of the replacement amount of the prodrug.

[0091] In some embodiments, the replacement amount of the prodrug is an equimolar amount compared to the amount of PBA being replaced

[0092] During the monitoring step, the patient is being treated with a mixture of phenylacetate or phenylbutyrate plus the new prodrug. The proportion depends upon what step of the transition the patient is in. The physician can also use information about the effects of a first step in setting the replacement amount of the prodrug for use in subsequent steps; thus if the prodrug is significantly more effective than predicted when the estimated amount used as a replacement amount is administered in a first step, the replacement amount used in a subsequent step of the transition can be proportionally reduced.

[0093] In another aspect, the invention provides a method to initiate treatment with phenylacetate, phenylbutyrate or a PBA prodrug in a step-wise fashion, as might be appropriate for a 'fragile patient' (a UCD patient with a history of frequent symptomatic hyperammonemia and/or neonatal onset disease who presumably has no urea synthetic capacity, or a patient with severely compromised liver function whose ability to metabolize the drug may be uncertain). This process may be more complex, since the prodrug will rely upon liver function to be activated and to function; thus the method is preferably done in a stepwise fashion, exemplified by the following steps:

- a) estimating or measuring dietary nitrogen intake for the patient; and/or

- b) estimating the patient's need for urinary waste nitrogen excretion; then
- c) administering a starting dose of the drug estimated to provide a fraction of the necessary waste nitrogen clearance as excreted PAGN; and
- d) increasing the dose of drug as appropriate, and repeating the steps above, to reach a maintenance dose of the drug.

[0094] The methods also include optionally measuring total urinary nitrogen and urinary PAGN after at least 3 days of drug administration, at which point a steady state has been achieved. It also can include calculating the amount of drug converted to PAGN, which would be expected to be at least 50%, to determine if the drug is having the desired effect. A suitable dosage of the drug would be identified as one where the amount of excreted PAGN is sufficient to clear the expected amount of waste nitrogen from the dietary intake of protein, which can be adjusted to account for the patient's endogenous nitrogen elimination capacity.

[0095] The fraction of nitrogen waste to be cleared in a single step can be selected with due regard to the severity of the patient's condition (nitrogen accumulation disorder). In some embodiments, it will be appropriate to target removal of about 50% of the waste nitrogen for which clearance assistance is needed. In some embodiments, the method will target removal of about 100% of the waste nitrogen.

[0096] In another aspect, the invention provides a method to transition a patient taking an initial daily dosage of phenylbutyrate from phenylbutyrate to HPN-100, comprising

- a) determining a suitable amount of HPN-100 to replace at least a portion of the initial daily dosage of phenylbutyrate;
- b) administering the suitable amount of HPN-100 to the subject along with an amount of phenylbutyrate corresponding to the initial daily dosage of phenylbutyrate minus an amount corresponding to the portion replaced by HPN-100;
- c) determining the level of excreted PAGN for the subject to make sure it has not decreased; and

- d) repeating steps a-c until all of the phenylbutyrate is replaced by HPN-100.

[0097] If it is found that the amount of excreted PAGN decreases, additional HPN-100 or additional PBA would be administered to reestablish a level of PAGN excretion that is suitable for the patient, and the replacement steps would then be continued until all of the PBA was replaced by HPN-100.

[0098] Here again, the portion of phenylbutyrate to be replaced in an initial step can be 100%, about 1/2, about 1/3, or about 1/4, or some value between these. During a stepwise process, where less than all of the phenylbutyrate is replaced in a first step, the patient will receive both HPN-100 and phenylbutyrate. As demonstrated herein, the appropriate method for determining a suitable dose of HPN-100 will take account of the excreted PAGN, rather than being based only on less reliable criteria for evaluating the orally delivered PBA prodrug.

[0099] In another embodiment, the invention provides a method to administer a phenylbutyrate prodrug to a patient, comprising determining the rate of PAGN excretion for the subject following administration of at least one phenylbutyrate prodrug, and selecting or adjusting a dose administration schedule based on the PAGN excretion rate. The compound can be a compound of Formula I, Formula II or Formula III as described above. Advantageously, the compounds used herein as prodrugs of PBA achieve nitrogen scavenging comparable to that of PBA but exhibit a slow-release kinetic profile that produces a more stable ammonia level in the treated subject. In some embodiments, the methods of the invention include administering a prodrug as described herein to a subject at a dosage that provides comparable ammonia level control to that achieved by PBA, but with significantly lower exposure of the subject to systemic PBA. In some embodiments, the subject experiences pharmacokinetic parameters for PBA that demonstrate lower exposure to PBA, including a lower AUC and C_{max} for PBA, while maintaining a plasma ammonia level comparable to or better than that provided by treatment with a dosage of PBA within the normal dosing range. When HPN-100 and PBA were administered to UCD patients at equimolar dosages, the patient receiving HPN-100 had overall lower plasma ammonia levels, and also lower PBA exposure:

	AUC (NH ₃) μg-hr/mL	C _{max} (NH ₃) μg-hr/mL	AUC (PBA) μg-hr/mL	C _{max} (PBA) μg-hr/mL
PBA	38.4(20)	79.1(40)	739(49)	141(44)
HPN-100	26.1(10)	56.3(28)	540(60)	70(65)

[00100] While a larger data set is needed to demonstrate statistical significance, limited amounts of data are available in part due to the rarity of these conditions. Nevertheless, the data indicates that PBA treatment resulted in less effective ammonia level control and greater exposure to PBA, while the PBA prodrug HPN-100 at equimolar dosing provided better ammonia level control and lower PBA exposure levels. Accordingly, in one aspect the invention provides a method to treat a UCD patient with a PBA prodrug, wherein the prodrug produces better ammonia level control than PBA without increasing the patient's exposure to PBA as judged by the AUC and C_{max} for PBA, when compared to treatment with an equimolar amount of PBA. In some embodiments, the treatment uses HPN-100 as the prodrug, and in some embodiments the AUC for PBA exposure is lower with the prodrug than with PBA by at least about 20%; or the exposure to PBA upon treatment with the prodrug is lower by at least about 30% compared to treatment with PBA; or both of these conditions are met to demonstrate reduced exposure to PBA. In some embodiments, the AUC for PBA is less than about 600 and the C_{max} for PBA is less than about 100 when the prodrug is administered. Preferably, the prodrug provides plasma ammonia levels that average less than about 40 μmol/L or not more than 35 μmol/L.

[00101] The advantageous slow-release kinetic profile of compounds used herein as prodrugs of PBA permits less frequent and more flexible dosing in selected patients as compared with sodium PBA. While all patients with UCDs and a propensity for elevated ammonia levels should in principle be able to benefit from the ammonia scavenging activity of HPN-100, UCD patients with substantial residual urea synthetic capacity (e.g. UCD whose first manifestations occur at several years of age or older; i.e. patients who do not exhibit neonatal onset) would be the best candidates for three times daily or even twice daily dosing with PBA prodrugs such as HPN-100. Patients with cirrhosis and HE would also be candidates for less frequent dosing, as even patients with severe liver disease have significant residual urea synthetic capacity (Rudman et al., *J. Clin. Invest.* 1973).

[00102] Specific embodiments of the invention include the following:

A. A method to determine an effective dosage of HPN-100 for a patient in need of treatment for a nitrogen retention disorder, which comprises monitoring the effect of an initial dosage of HPN-100, wherein monitoring the effect consists essentially of determining the patient's urinary phenylacetyl glutamine (PAGN) output.

In this method, the initial dose for a treatment-naïve patient would take into account the expected percentage conversion of the administered PBA to urinary PAGN, and urinary PAGN output can be determined as a ratio of urinary PAGN to urinary creatinine, since it has been demonstrated by others that creatinine, the daily excretion of which tends to be constant for a given individual, can be used as a means to normalize measures of urinary parameters while correcting for variations in urinary volume. In these methods, the nitrogen retention disorder can be chronic hepatic encephalopathy or a urea cycle disorder. Plasma ammonia levels may also be monitored to adjust the overall treatment program and dietary protein intake, but as discussed above, urinary PAGN provides a preferred way to assess the drug's role in waste nitrogen elimination.

B. A method to determine an effective dosage of HPN-100 for a patient in need of treatment for a nitrogen retention disorder, which comprises monitoring the effect of an initial dosage of HPN-100, wherein the initial dose for a treatment-naïve patient would take into account the expected percentage conversion of the administered PBA to urinary PAGN, and wherein monitoring the effect of the initial dosage of HPN-100 consists essentially of determining the patient's urinary phenylacetyl glutamine (PAGN) output and/or total urinary nitrogen. In these methods, administering the effective dosage of HPN-100 to the patient preferably produces a normal plasma ammonia level in the patient. This can be a level of about 35 or about 40 $\mu\text{mol/L}$.

C. A method to determine a starting dosage of HPN-100 for a patient having a nitrogen retention disorder, which comprises calculating the dosage of HPN-100 based on a utilization efficiency of about 60% to about 75%. In such methods, the dosage of HPN-100 can be calculated from the patient's dietary protein intake, or it can be estimated from the patient's body weight and approximate growth rate. In such methods, the dosage of HPN-100 is sometimes reduced to account for the patient's residual urea synthesis capacity, by adjusting the amount of HPN-100 to reflect the amount of ammonia scavenging needed in view of the patient's endogenous capacity for nitrogen elimination.

D. A method to determine a dosage of a PAA prodrug for a patient having a nitrogen retention disorder, comprising:

- a) determining the patient's residual urea synthesis capacity;

- b) determining the patient's dietary protein intake;
- c) estimating from a) and b) the patient's target urinary PAGN output;
- d) determining an amount of the PAA prodrug needed to mobilize the target amount of urinary PAGN based on about 60% to about 75% conversion of the PAA prodrug into urinary PAGN.

In these methods, the PAA prodrug can be phenylbutyric acid (PBA) or a pharmaceutically acceptable salt thereof, or it can be HPN-100.

E. A method to treat a patient having an ammonia retention disorder with a suitable dosage of a PAA prodrug, comprising:

- a) determining the patient's residual urea synthesis capacity;
- b) determining the patient's dietary protein intake;
- c) estimating from a) and b) the patient's target urinary PAGN output;
- d) determining an amount of the PAA prodrug needed to mobilize the target amount of urinary PAGN based on about 60% to about 75% conversion of the PAA prodrug into urinary PAGN; and
- e) administering to the patient the suitable dosage of the PAA prodrug.

In these methods, the PAA prodrug is often phenylbutyrate or a pharmaceutically acceptable salt thereof, or HPN-100.

G. A method to transition a patient receiving treatment with an initial amount of phenylacetate or phenylbutyrate to a final amount of HPN-100, comprising:

- a) determining a replacement amount of HPN-100 to replace at least a portion of the phenylacetate or phenylbutyrate;
- b) substituting the replacement amount of the HPN-100 for the phenylacetate or phenylbutyrate; and
- c) monitoring the amount of urinary PAGN excreted by the patient to assess the effectiveness of the replacement amount of the HPN-100.

In these methods, an increase the amount of urinary PAGN may indicate that the amount of HPN-100 can be reduced, and a decrease in urinary PAGN may indicate the amount of HPN-100 needs to be increased.

H. A method to transition a patient taking an initial daily dosage of phenylbutyrate from phenylbutyrate to HPN-100, comprising

- a) determining a suitable amount of HPN-100 to replace at least a portion of the initial daily dosage of phenylbutyrate;
- b) administering the suitable amount of HPN-100 to the subject along with an amount of phenylbutyrate corresponding to the initial daily dosage of phenylbutyrate minus an amount corresponding to the portion replaced by HPN-100;
- c) determining the level of excreted urinary PAGN for the subject; and
- d) repeating steps a-c until all of the phenylbutyrate is replaced by HPN-100.

I. A method to initiate treatment with phenylacetate, phenylbutyrate or a HPN-100 in a step-wise fashion, comprising:

- a) estimating or measuring dietary nitrogen intake for the patient; and/or
- b) estimating the patient's need for urinary waste nitrogen excretion based upon diet and urea synthetic capacity; then
- c) administering a starting dose of the drug estimated to provide a fraction of the necessary waste nitrogen clearance as urinary PAGN taking into account the expected percentage conversion of the administered PBA to urinary PAGN; and
- d) increasing the dose of drug as appropriate, and repeating the steps above, to reach a maintenance dose of the drug.

J. A method to treat a UCD patient with a PBA prodrug, wherein the prodrug produces equivalent or better ammonia level control compared to PBA without increasing the patient's exposure to PBA as judged by the AUC and Cmax for PBA when the patient receives the PBA prodrug, when compared to the AUC and Cmax observed when the patient receives an equimolar amount of PBA.

In these methods, the PBA prodrug is often HPN-100.

The methods include a method to treat a patient having a nitrogen retention disorder with the PBA prodrug HPN-100, wherein the AUC for PBA exposure can be lower with the prodrug than with PBA by at least about 20%, or by at least about 30% compared to treatment with PBA. This is believed to be related to the slow absorption or uptake characteristics of HPN-100, which

provide a more stable level of PBA exposure and provide an unexpected advantage of HPN-100 to be effective with less frequent dosing when compared to sodium phenylbutyrate.

K. A method to determine a suitable dietary protein level for a patient having a nitrogen retention disorder, comprising:

- a) determining the patient's endogenous nitrogen elimination capacity;
- b) calculating from the endogenous nitrogen elimination capacity an amount of dietary protein the patient can process without the aid of a nitrogen scavenging drug;
- c) then adding an amount of protein that the patient should be able to process with the assistance of selected dosage of a nitrogen scavenging drug to arrive at an amount of dietary protein the patient can have while being treated with the selected dosage of the nitrogen scavenging drug, taking into account the amount of protein required for health and body growth.

In this method, the nitrogen scavenging drug can be HPN-100. Commonly, the selected dosage of HPN-100 is not more than about 19 grams per day, and the amount of dietary protein the patient should be able to process with the assistance of this amount of HPN-100 is about 1 grams (~1.3 g) of protein per gram of HPN-100.

L. A method to treat a patient with a PBA prodrug, comprising administering HPN-100 at a daily dose in excess of 19 g per day to a subject having HE or UCD.

Optionally, the daily dose of HPN-100 is between about 20 g and about 57 g.

M. A method for determining the dosing schedule of a PBA prodrug wherein the patient retains substantial residual urea synthetic capacity, as would be the case for most patients with cirrhosis and HE or most UCD patients who do not exhibit symptoms within the first two years of life.

[00103] In the foregoing methods that utilize HPN-100, the exposure to PBA upon treatment with the prodrug HPN-100 is lower by at least about 30% compared to treatment with PBA. Also, commonly the AUC for PBA is less than about 600 and the C_{max} for PBA is less than about 100 when the prodrug is administered. Also, in the foregoing methods, when the subject is treated with the prodrug, which can be HPN-100, the subject will typically achieve and maintain normal plasma ammonia levels.

[00104] The following examples are offered to illustrate but not to limit the invention.

[00105] The data below from three human studies and one preclinical study illustrate that the conventional approach of assessing drug exposure and effect by measuring blood levels does not correlate with nitrogen scavenging as assessed by urinary excretion of PAGN or by reduction of plasma ammonia. These data demonstrate that, surprisingly, the plasma level of PBA or PAA seen with an effective amount of a prodrug can be far less the plasma level of PBA or PAA seen with a similarly effective amount of phenylbutyrate. Moreover, they demonstrate the need to allow for incomplete conversion of sodium PBA or HPN-100 into PAGN in selecting starting dosage, the delayed release behavior and implications for dosing schedule of delivering PBA as a triglyceride rather than as a salt, and the possibility of administering HPN-100 in doses greater than those currently recommended for sodium PBA. These are followed by a biological explanation for the findings.

Example 1

Single dose safety and PK in healthy adults

[00106] To assess its pharmacokinetic (PK) and pharmacodynamic (PD) profile, HPN-100 was administered as a single dose to 24 healthy adults. Pharmacokinetic samples were taken pre-dose and at 15 and 30 minutes post-dose and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, and 48 hours post-dose. As discussed below, plasma levels of the major HPN-100 metabolites PBA, PAA and PAGN were many fold lower after administration of HPN-100 than after sodium PBA. By contrast, urinary excretion of PAGN was similar between the two groups (4905 +/- 1414 mg following sodium PBA and 4130 +/- 925 mg following HPN-100) and the differences that were observed were determined to be largely an artifact of incomplete collection due to stopping urine collection at 24 hours (note that PAGN excretion following administration of sodium PBA was largely complete at 24 hours but continued beyond 24 hours following administration of HPN-100). Thus, the plasma metabolite concentrations did not accurately reflect the comparative ammonia scavenging activity of sodium PBA and HPN-100.

[00107] Three healthy adult volunteers were treated with a single dose of either sodium PBA or HPN-100 at a dosage of 3 g/m². Plasma levels of PAA, PBA, and PAGN were monitored periodically for 12-24 hours by known methods. Results of this are shown in Figure 4, which shows a curve for each subject (note the log scale).

[00108] In each panel, the curves represent measured levels of PBA, PAA or PAGN in subjects receiving sodium PBA at $3\text{g}/\text{m}^2$ dosage, or HPN-100 in an amount calculated to provide an equimolar amount of PBA to that provided by the sodium PBA dosage. Three curves for each material are for three subjects who received the specified dosages of sodium PBA or HPN-100.

[00109] In the left panel, the upper curve represents PBA levels; the intermediate one represents PAA levels; and the lowest of the three sets of lines represents PAGN levels. In the right panel, the three lowest curves at the 10-15 hour time span are all for PBA; and the highest three curves at 15-25 hours represent PAGN levels. PAA levels were not determined after approximately 12 hours, and were generally close to the PAGN curves up to that time.

Example 2

Administration of HPN-100 to patients with liver disease

[00110] To determine its pharmacokinetic (PK) and pharmacodynamic (PD) profile in patients with liver disease, clinical testing was conducted in which HPN-100 was administered orally as a single dose (100 mg/kg/day on day 1), and twice daily for 7 consecutive days (200 mg/kg/day on days 8 through 14, in two doses of 100 mg/kg per dose), to subjects with hepatic impairment with cirrhosis (Child-Pugh scores of A, B, or C) and to a gender and age-matched control group of healthy adults with normal hepatic function. On day 15, subjects received a single dose of HPN-100 (100 mg/kg). PK blood samples were taken pre-dose, at 15 and 30 minutes post-dose, and at 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours post-dose on days 1, 8, and 15, and at 48 hours after dosing on days 1 and 15. On days 9–14, blood samples were taken pre-morning dose and at 2 hours post-morning dose. Urine was collected 0–4, 4–8, 8–12, and 12–24 hours post-dose on days 1, 8, and 15, and at 24–48 hours post-dose on days 1 and 15.

[00111] HPN-100 was metabolized via the predominant pathway in all subject groups, and the alternative HPN-100 metabolites PAG (phenylacetyl glycine), PBG (phenylbutyryl glycine), and PBGN (phenylbutyryl glutamine) were below the limit of quantification in all plasma samples. Both the extent of systemic exposure (AUC_{0-t}) and C_{max} for PBA and PAA tended to be higher in Child-Pugh group B or C than in Child-Pugh group A or the healthy volunteer group, although there were no significant differences in these variables on day 15. As described below, plasma PAA levels did correlate with Childs-Pugh classification (i.e. were higher in patients with more severe liver disease). However, the average conversion of HPN-100 to PAGN was ~ 75%, and no difference were seen between patients with cirrhosis and normal healthy volunteers, demonstrating that hepatic impairment did not affect the subjects' ability to activate the PBA prodrug HPN-100 or

to utilize it for elimination of excess ammonia. Thus, as summarized in more detail below, plasma metabolite levels did not correlate well with the HPN-100 dosage and, just as for healthy adults, plasma metabolite levels did not accurately reflect the nitrogen scavenging effect of HPN-100. Moreover, the mean conversion of administered PAA to PAGN averaged ~75% in this patient population.

Analyte	Subject group	Geometric mean ratio	90% CI	P value for group effect
PBA	AUC_{0-t}			0.40
	Child-Pugh A	0.92	0.58–1.43	
	Child-Pugh B	1.26	0.80–1.97	
	Child-Pugh C	1.37	0.87–2.14	
PBA	C_{max}			0.52
	Child-Pugh A	1.42	0.87–2.31	
	Child-Pugh B	1.35	0.83–2.21	
	Child-Pugh C	1.50	0.92–2.45	
PAA	AUC_{0-t}		0.48–3.06	0.64
	Child-Pugh A	1.22	0.61–3.85	
	Child-Pugh B	1.53	0.77–4.88	
	Child-Pugh C	1.94		
PAA	C_{max}			0.72
	Child-Pugh A	1.33	0.70–2.52	
	Child-Pugh B	1.16	0.61–2.20	
	Child-Pugh C	1.52	0.80–2.88	

AUC_{0-t}, area under the plasma concentration curve from time 0 to the last measurable concentration; CI, confidence interval; C_{max}, maximum observed plasma concentration; PAA, phenylacetic acid; PBA, phenylbutyric acid.

[00112] During multiple dosing (days 8–15), there was a trend for higher systemic concentrations of PBA and PAA in subjects with greater hepatic impairment (Child-Pugh B or C) compared with Child-Pugh group A and the healthy volunteers. Unlike PBA, PAA did accumulate significantly in plasma during multiday dosing. Differences between single (day 8) and multiple dosing (day 15: steady state) were significant for AUC₀₋₁₂ and C_{max} of PAA for all subjects

combined ($p < 0.001$), but not for PBA. After dosing on day 15, extent of exposure to PAA, but not PBA, significantly correlated with hepatic impairment.

[00113] The clinical efficacy of HPN-100 is dependent on its ammonia scavenging capabilities, through conjugation of glutamine with PAA to form PAGN. After dosing on each day, PAGN was the major metabolite excreted: 42–49% of the HPN-100 dose administered was excreted as PAGN on day 1, 25–45% on day 8, and 58–85% on day 15. Very low amounts of PBA and PAA were excreted in the urine ($\leq 0.05\%$ of the total HPN-100 dose). There were no significant differences in the amount of PAGN excreted between any of the Child-Pugh groups and the healthy volunteers. Urinary PAGN excretion is also an indication of the ammonia-scavenging capacity of HPN-100, as 2 moles of ammonia combine with 1 mole of PAA to produce PAGN. Hepatic impairment had no significant effect on the ammonia-scavenging ability of HPN-100 in this study. There were no significant differences in the amount of PAGN excreted between any of the Child-Pugh groups and the healthy volunteers. The observations that hepatic impairment had no significant effect on the ammonia-scavenging ability of HPN-100 in this study but was associated with accumulation of PAA in plasma underscores the importance of utilizing urinary PAGN rather than metabolite blood levels to guide drug effect and, as a corollary, the importance of the invention, as does the fact that the mean percentage conversion of administered PAA into urinary PAGN among the 4 treatment groups was ~75%.

Urinary PAGN Excretion After Dosing on Day 15 (0-48 Hours).

	Child-Pugh A (8)	Child-Pugh B (8)	Child-Pugh C (8)	Healthy Adults (8)
Amount excreted (μmol) Mean (SD) Range	31431 (15291) 16016–65229	25152 (11426) 13643–41635	30752 (20860) 6331–60139	28716 (8223) 17203–41092
Molar % of dose excreted Mean (SD) Range	79.6 (30.5) 48.9–138.2	58.2 (29.2) 26.5–99.6	85.0 (65.1) 23.1–221.1	68.6 (21.9) 30.6–96.
Molar % of dose ammonia scavenged Mean (SD) Range	159.2 (60.9) 97.9–276.4	116.3 (58.3) 53.0–199.2	169.9 (130.1) 46.3–442.3	137.2 (43.9) 61.3–193.4

[00114] Of particular note, there was no relationship between the plasma levels of PBA and PAA, which exhibited a non-statistically significant directional change toward higher plasma levels in patients with liver disease than healthy adults, and urinary excretion of PAGN.

EXAMPLE 3

Administration of HPN-100 To Adults With UCDs

[00115] To further explore its pharmacokinetic (PK) and pharmacodynamic (PD) profile in clinical states associated with nitrogen retention, 10 adult UCD patients were switched from sodium PBA to a PBA equimolar dose of HPN-100. Subjects were required to be on a stable dose of sodium PBA before enrolment. Upon enrolment, all subjects received sodium PBA for 7 days and were then admitted to a study unit (Visit 2-1) for overnight observation and 24-hour PK and ammonia measurements and urine collections. Subjects were then converted to the PBA equimolar dose of HPN-100, either in a single step or in multiple steps depending on the total dose of sodium PBA; 9 out of 10 patients converted in a single step. Subjects stayed on the 100% HPN-100 dose for one week and were then re-admitted to the study unit for repeated PK (Visit 11-1), ammonia and urine collections.

[00116] The findings from this study, summarized in detail below, demonstrate that, just as in healthy adults and patients with liver disease, plasma metabolite levels do not correlate well with ammonia scavenging activity as reflected by urinary PAGN excretion and corroborated by plasma ammonia results. Moreover, the findings demonstrate considerable inter-individual variability in the percentage of both sodium PBA and HPN-100 that is converted to urinary PAGN.

[00117] Pharmacokinetic, ammonia and safety analyses: As summarized in the table below, 7 days of HPN-100 administration resulted in comparable PAA and plasma PAGN levels but slightly lower PBA levels compared to the PBA molar equivalent dose of sodium PBA.

Comparison of Pharmacokinetic Parameters at Steady State – sodium PBA vs. HPN-100

PK Parameter	Arithmetic Mean (CV %)	
	Sodium PBA (N=10)	HPN-100 (N=10)
PBA in Plasma		
AUC ₀₋₂₄ (µg·h/mL)	739 (49.2)	540 (60.1)
C _{max_{ss}} (µg/mL)	141 (44.3)	70.1 (64.7)
C _{min_{ss}} (µg/mL)	0.588 (255)	2.87 (265)

PK Parameter	Arithmetic Mean (CV %)	
	Sodium PBA (N=10)	HPN-100 (N=10)
PAA in Plasma		
AUC ₀₋₂₄ (µg·h/mL)	595.6 (123.9)	574.6 (168.9)
C _{max_{ss}} (µg/mL)	53.0 (94.7)	40.5 (147.6)
C _{min_{ss}} (µg/mL)	3.56 (194.4)	7.06 (310.7)
PAGN in Plasma		
AUC ₀₋₂₄ (µg·h/mL)	1133 (31.1)	1098 (44.2)
C _{max_{ss}} (µg/mL)	83.3 (25.8)	71.9 (56.0)
C _{min_{ss}} (µg/mL)	16.8 (86.1)	12.1 (134.4)

AUC₀₋₂₄: Area under the concentration from time 0 (pre-dose) to 24 hours, C_{max_{ss}}: Maximum plasma concentration at steady state, C_{min_{ss}}: Minimum plasma concentration at steady state, A_e: Amount excreted over 24 hours

¹ The mean (SD) sodium PBA dose = 12.6 (4.11) g; the mean (SD) HPN-100 dose = 12.3 (3.91) g.

[00118] Despite dissimilar PBA blood levels, overall urinary excretion of PAGN was similar for the two treatments as summarized in the table below. Importantly, and in contrast to the assumptions inherent in current treatment guidelines that all administered sodium PBA is converted to urinary PAGN, considerable inter-individual variability was observed in the percentage of administered PAA converted to PAGN, which averaged ~60% and similar both sodium PBA and HPN-100. Moreover, the 24 hour pattern of excretion appeared to differ in that urine output of PAGN reached its highest level during the ‘afternoon hours’ (6-12 hour urine collection) for patients treated with sodium PBA, whereas peak output of PAGN occurred overnight (12-24 hour urine collection) for patients on HPN-100 treatment. This difference presumably reflects the slow release characteristics and longer duration of effective blood concentrations of PAA following administration of HPN-100 as compared with sodium PBA. HPN-100 was either not detectable or below the limits of quantitation in all blood samples.

Comparison of Mean PAGN Amount Excreted (µg) – sodium PBA (sodium phenylbutyrate) vs. HPN-100

Treatment	PAGN 0-6 hours	PAGN 0-12 hours	PAGN 12-24 hours	Total PAGN Excretion (CV %)
sodium PBA	2,452,838	4,859,121	4,645,447	12,153,473 (48.2)
HPN-100	2,381,371	3,027,310	5,433,033	10,784,747 (25.9)

[00119] As summarized in the table below, mean time normalized area under the curve (TN-AUC) values for venous ammonia following HPN-100 were directionally (~31%) lower than those

observed with sodium PBA (26.1 vs. 38.4 $\mu\text{mol/L}$) although the differences did not achieve statistical significance (Figure 10). Likewise, peak venous ammonia concentrations following HPN-100 were directionally (~29%; not statistically significant) lower than those observed with sodium PBA (56.3 vs. 79.1 $\mu\text{mol/L}$, respectively).

[00120] The normal upper limit for venous ammonia varied among the study sites from 26 to 35 $\mu\text{mol/L}$. Examination of ammonia values (TN-AUC) for individual patients demonstrated that patients with higher ammonia levels on sodium PBA exhibited greater decreases in ammonia values following administration of HPN-100 (Figure 12). Moreover, the mean ammonia value after HPN-100 (26.1 $\mu\text{mol/L}$) was within the normal range while it was above the upper limit of normal (ULN) after sodium PBA (sodium phenylbutyrate) (38.4 $\mu\text{mol/L}$) (Figure 13). Likewise the mean percentage of normal ammonia values increased from 58% after sodium PBA treatment to 83% after HPN-100 treatment.

Venous Ammonia Pharmacodynamics Following Seven Days of Dosing With Either Sodium PBA or HPN-100 (Steady State)

Subject	Sodium PBA			HPN-100		
	$C_{\text{max,ss}}$ ($\mu\text{mol/L}$)	TN-AUC ($\mu\text{mol/L}$)	PBA Equivalent dose ¹	$C_{\text{max,ss}}$ ($\mu\text{mol/L}$)	TN-AUC ($\mu\text{mol/L}$)	PBA Equivalent dose ¹
1001	29.0	16.47	17.5	63.0	19.8	13.1
1002	31.0	20.9	15.8	31.0	19.3	15.9
1004	85.0	46.8	99.2	106	35.1	9.16
1006	150	71.5	17.5	13.0	8.30	17.7
2001	88.0	52.1	6.57	33.0	22.7	6.71
2003	31.0	17.5	11.8	74.0	21.1	12.2
3002	108	22.3	16.5	36.0	21.9	17.7
3004	115	62.9	13.1	75.0	38.4	13.1
5001	82.2	35.8	8.76	57.0	35.5	8.85
5002	72.2	37.7	8.76	75.2	39.1	8.85
N	10	10	10	10	10	10
Mean	79.1	38.4	12.6	56.3	26.1	12.3
SD	40.1	19.6	4.11	27.9	10.3	3.91
Median	83.6	36.8	12.5	60.0	22.3	12.7
Min	29.0	16.4	6.57	13.0	8.30	6.71
Max	150	71.5	17.5	106	39.1	17.7
25%	31.0	20.0	--	32.5	19.7	--
75%	110	54.8	--	75.0	36.2	--

[00121] This reduction in ammonia exposure among UCD patients reflects better overnight control among subjects receiving HPN-100, as summarized in the table below and in Figure 11. This study shows that both AUC and Cmax for ammonia were lower with HPN-100, indicating less total ammonia exposure, and especially at night, HPN-100 exhibited a significantly stronger effect. While not statistically significant due to the small population size, this demonstrates that HPN-100 is at least as effective, and apparently more so, than PBA on an equimolar basis based on the key measure, its ability to mobilize ammonia for urinary elimination. Based on preliminary results, HPN-100 also provides more stable ammonia levels, and reduces risk of hyperammonemia. In this trial, 9 of 10 subjects who experienced both HPN-100 and sodium PBA indicated a preference for HPN-100.

[00122] In addition, in this trial, no serious adverse effects (SAEs) were observed in patients taking HPN-100, while two subjects receiving PBA experienced symptomatic hyperammonemia; and the total number of adverse effects (AEs) reported among subjects taking HPN-100 (5 subjects reported a total of 15 AEs) was lower than the number of AEs among subjects taking PBA (7 subjects reported 21 AEs).

[00123] The following table summarizes overall comparative data for sodium PBA and HPN-100, administered at equimolar rates (n=10) (see tables above and figures 10-13 for additional detail).

Parameter	Sodium PBA	HPN-100
NH ₃ : Total AUC	38.4 ± 19.6	26.1 ± 10.3
NH ₃ Cmax	79.1 ± 40.1	56.3 ± 27.9
NH ₃ exposure: DAY (hours 6-12)	37.1	32.9
NH ₃ exposure: NIGHT (hours 12-24)	36.3	21.3
Adverse effects	21 reported by 7 subjects	15 reported by 5 subjects
Serious adverse effects	2 (symptomatic hyperammonemia)	0
PAGN excretion	Comparable	Comparable

[00124] While the differences between sodium PBA and HPN-100 did not reach statistical significance due to the small sample size, HPN-100 exhibited a clear trend toward being more efficacious at equimolar dosages, and it was particularly effective for improving overnight control of ammonia levels.

[00125] Figure 9a demonstrates that PBA levels in the blood are not correlated with HPN-100 dosages received. It plots the 24-hour AUC for PBA and the C_{max} for PBA against HPN-100 dosage (top panel), and while the AUC and C_{max} track together in each patient, they show no relationship to HPN-100 dose: both the highest and the lowest PBA exposures occurred in patients receiving high doses of HPN-100. Figure 9b shows that levels of PAA are similarly uncorrelated with HPN dosages.

[00126] Figure 10 illustrates the trend shown in the clinical testing, where HPN-100 provided better overall control of waste nitrogen.

[00127] Figure 11 illustrates that improved night time control of excess ammonia is achieved with HPN-100.

[00128] Figure 12 shows that especially for patients with higher ammonia levels when treated with sodium PBA (Na PBA), HPN-100 provides better control than sodium PBA, while in patients with lower ammonia levels (ones for whom sodium PBA seems to work relatively well), HPN-100 provides at least comparable ammonia control. Note that for patients having ammonia levels above about 40 $\mu\text{mol/L}$ when treated with sodium PBA, HPN-100 at equimolar dosages provided superior control of ammonia, and consistently reduced ammonia levels to below about 40 $\mu\text{mol/L}$. Thus for patients whose ammonia levels are abnormal (e.g. above about 40 $\mu\text{mol/L}$) when treated with sodium PBA, it is expected that better ammonia control can be achieved with an equimolar amount of HPN-100. Based on this, dosages of HPN-100 can be determined as set forth herein. Figure 13 illustrates that ammonia levels were better controlled in this test by HPN-100 than with sodium PBA, e.g., the average ammonia levels are lower, and tend to be below the upper limit for normal.

Example 4

Relationship Between Ammonia Control and Urinary PAGN Excretion

[00129] As part of the clinical study in UCD patients described in the example above (Example 3), the relationship between plasma ammonia levels and urinary excretion of PAGN was examined.

Unlike blood levels of PAA or PBA which exhibited no consistent relationship to ammonia levels (i.e. ammonia control), blood ammonia assessed as the time-normalized area under the curve exhibited an inverse curvilinear relationship to urinary PAGN. That is, plasma ammonia decreased as urinary PAGN increased. Moreover, the relationship between ammonia and urinary PAGN excretion did not differ between sodium PBA and HPN-100 suggesting that this method of dose determination is independent of product formulation. Figure 5 shows a plot of Plasma Ammonia (TN-AUC) versus Urinary PAGN Excretion.

Example 5

Experimentation With Dosing Schedule

[00130] The results of single dose PK/PD modeling observed in the examples above suggested that HPN-100 exhibits delayed release characteristics as compared with sodium PBA with a corresponding potential for increased flexibility in dosing, which was further explored in additional clinical studies described above. In one of these, HPN-100 was administered twice daily as well as in the fasted and fed state. In the other, HPN-100 was administered three times daily with meals. Both 3x daily and 2x daily dosing resulted in a similar proportion of PAGN excreted in the urine and, as demonstrated in adult UCD patients, three times daily dosing was associated with effective ammonia control.

[00131] In Example 2, a number of secondary statistical analyses comparing PK variables after fed versus fasted HPN-100 dosing and single versus multiple HPN-100 dosing were also done. There were no PK or PD differences observed when HPN-100 was administered after fasting (day 1) or with a meal (day 8). Accordingly, it is believed that HPN-100 can be effectively administered without the need for it to accompany a meal, while the label and package insert for sodium PBA (sodium PBA) indicate that it should be taken with meals. In addition to the lack of difference for PAA PK variables between the fasted and fed states (Days 8 vs 1), the table below also illustrates plasma accumulation of PAA that occurs with multiple dosing (Days 15 vs. 8).

Plasma PK Variables For PAA

PK variable	Child-Pugh A (n = 8)	Child-Pugh B (n = 8)	Child-Pugh C (n = 8)	Healthy volunteers (n = 8)
AUC₀₋₁₂ [(µg/mL)·h]				
Day 1				
Geo. mean (range)	37.33 (7.29–78.42)	72.20 (23.38–174.73)	48.59 (4.75–312.43)	50.63 (14.27–150.00)
CV%	53.41	64.91	109.58	79.59
Day 8				
Geo. mean (range)	39.64 (5.96–153.14)	73.44 (26.83–279.48)	86.36 (28.12–367.70)	34.07 (5.27–134.99)
CV%	78.73	85.58	92.85	80.59
Day 15				
Geo. mean (range)	117.89 (23.28–413.43)	138.95 (40.21–652.99)	184.26 (14.97–2245.51)	99.16 (30.06–394.79)
CV%	76.82	99.48	170.56	88.59
AUC_{0-t} [(µg/mL)·h]				
Day 1				
Geo. Mean (range)	37.33 (7.29–78.42)	72.20 (23.38–174.73)	48.59 (4.75–312.43)	50.63 (14.27–150.00)
CV%	53.41	64.91	109.58	79.59
Day 15*				
Geo. Mean (range)	121.57 (23.28–528.73)	153.00 (40.21–938.85)	194.17 (14.97–3415.51)	99.94 (30.06–420.32)
CV%	92.27	118.54	198.42	93.08
C_{max} [µg/mL]				
Day 1				
Geo. mean (range)	9.65 (2.58–26.93)	13.52 (6.94–27.97)	10.95 (2.68–40.30)	11.81 (4.14–29.79)
CV%	63.78	57.70	82.65	68.72
Day 8				
Geo. mean (range)	10.21 (1.64–25.66)	14.78 (4.46–42.02)	16.03 (6.49–48.07)	10.03 (2.90–28.43)
CV%	62.25	74.53	72.29	66.97
Day 15[†]				
Geo. mean (range)	29.07 (7.29–53.48)	25.46 (10.54–65.40)	33.28 (5.03–208.80)	21.92 (7.76–61.31)
CV%	44.21	64.26	121.51	62.88
t_{1/2} [h][‡]				
Day 1				
Mean (SD)	0	0	2.10 (0.32)	0
Range			1.88–2.33	
Day 15				
Mean (SD)	1.80 (0.94)	2.76 (1.53)	7.70	1.91 (0.37)
Range	1.01–3.14	1.68–3.84	7.70–7.70	1.68–2.33
T_{max} [h]				
Day 1				
Median (range)	3.50 (2.00–6.00)	5.00 (3.00–8.00)	5.00 (2.00–8.00)	6.00 (4.00–6.00)
Day 8				
Median (range)	4.00 (2.00–6.00)	5.00 (3.00–8.00)	5.00 (4.00–8.00)	4.00 (3.00–6.00)
Day 15				
Median (range)	4.00 (2.00–6.00)	4.00 (3.00–8.00)	5.00 (0.00–8.00)	4.00 (3.00–4.00)

*p = 0.64 for group effect; [†]p = 0.72 for group effect

[‡]On day 1, n = 2 in Child-Pugh group B and n = 0 in all other groups; on day 15, n = 4 in group A, 2 in group B, 1 in group C, and 3 in group D

AUC₀₋₁₂, area under the plasma concentration curve from time 0 up to 12 hours after dosing; AUC_{0-t}, area under the plasma concentration curve from time 0 to the last measurable concentration; C_{max}, maximum observed plasma concentration; CV, coefficient of variation; geo. Mean, geometric mean; n, number of subjects; SD, standard deviation; T_{max}, time to maximum observed plasma concentration; t_{1/2}, half-life

Example 6

PK/PD Modeling Results

[00132] In the case of most drugs, the fraction of an orally administered dose which is removed and metabolized by the liver prior to reaching the systemic circulation (i.e. first pass effect) is not considered bioavailable, since it does not enter the systemic circulation and therefore is not able to reach its target organ or receptor. However, this is not the case for ammonia scavenging drugs described in this invention. Since hepatocytes and possibly enterocytes contain the enzymes necessary for conversion of PBA to PAA and conversion of PAA to PAGN and since glutamine is present in the splanchnic as well as the systemic circulation, it is likely that PBA can be converted to PAGN prior to reaching the systemic circulation (i.e. “pre-systemically”) and that this PBA is fully effective with respect to ammonia scavenging (Figure 6); i.e. fully active. To verify this possibility, PK/PD modeling using NONMEM VI (Icon, Ellicott City, MD.) was carried out on plasma and urinary metabolite data (over 5000 data points) from the clinical studies described above involving healthy adults, subjects with cirrhosis and UCD subjects. The results of this PK/PD modeling have validated the model depicted in Figure 3. Moreover, the modeling has verified that HPN-100 exhibits slow release characteristics as compared with sodium PBA and provided an explanation for the poor correlation between blood levels of PBA/PAA and ammonia and the importance of urinary PAGN is dose adjustment. Key conclusions resulting from the PK/PD modeling were as follows

1. PBA is more slowly absorbed (~40% as fast) from the intestine after administration of HPN-100 versus sodium PBA (absorption rate constants and absorption half-lives for HPN-100 and sodium PBA are 0.544 h^{-1} vs. 1.34 h^{-1} and 1.27 h vs. 0.52 h , respectively).
2. The lower plasma levels of PBA following administration of HPN-100, as compared with sodium PBA, reflect results indicating a fractionally greater amount of PBA (31% vs. 1%) being converted pre-systemically (to PAA and PAGN) following administration of HPN-100 than Na PBA.
3. In a dataset containing healthy, cirrhotic, and UCD individuals, diagnosis was introduced as a covariate on the estimated bioavailability of HPN-100 revealing a 32% lower estimated bioavailability of PBA in healthy adults compared to adult UCD patients. Cirrhotic and UCD patients had similar PBA bioavailability following HPN-100 treatment.

Example 7

ADME Study In Three Cynomolgous Monkeys

[00133] To assess the preclinical handling of ammonia scavenging drugs, 600 mg/kg of either radio labeled sodium PBA or radio labeled HPN-100 was administered as a single dose to 3 cynomolgous monkeys. These monkeys were chosen because, like humans (and unlike most other species), they metabolize PAA to PAGN and thus provide a useful model for testing prodrugs of PAA. This study corroborated clinical findings summarized in Examples 1-3, including the following: (a) dosing with oral sodium PBA or oral HPN-100 did not result in 100% conversion to urinary PAGN, (b) plasma PBA and PAA blood levels did not correlate consistently with ammonia scavenging activity as reflected by urinary PAGN output, and (c) HPN-100 exhibited slow release characteristics as compared with sodium PBA.

[00134] Radio labeled PBA and PAA entered the systemic circulation rather slowly following administration of radio labeled HPN-100 [C_{max} for PBA was achieved 1.5 hours post-dosing (52.2 µg/mL) and C_{max} for PAA was achieved 8 hours post dosing (114 µg/mL)], corroborating the findings observed in humans (including the PK/PD modeling), and essentially no HPN-100 appeared in systemic circulation or in excretions. About 90% of radioactive material derived from HPN-100 that was excreted in urine was PAGN, accounting for 39% of the administered HPN-100. By contrast, when oral sodium PBA was administered, PAGN accounted for only 23% of the radio labeled material, and unchanged PBA accounted for 48% of the administered dosage of oral sodium PBA. Thus oral sodium PBA was utilized less efficiently than HPN-100, and an unexpectedly high amount of PBA was excreted unchanged.

Example 8

Biological and Anatomical Considerations

[00135] Unlike most drugs which act on a target organ/cell/receptor (etc.) perfused by systemic blood, ammonia scavenging drugs of the types covered by this invention do not act on a target organ, rather they act through the combination of PAA with glutamine to form PAGN (Figure 6). Since glutamine is present in the splanchnic as well as the systemic circulation and since the liver is a metabolically active organ capable of catalyzing all steps involved in the conversion of HPN-100 or PBA to PAA and then to PAGN, the data accumulated to date, including the PK/PD modeling, as well as anatomical consideration lead us to the conclusion that the formation of PAGN from PBA/PAA occurs to a significant degree before PBA/PAA reach the systemic

circulation (e.g. within the liver). This is especially true when HPN-100 is administered as a PBA prodrug. This explains the poor correlation between plasma levels and ammonia trapping effects and leads to the conclusion that the dosing and dose adjustment of these PBA prodrugs should be based on urinary excretion of PAGN and total urinary nitrogen. Figure 6 illustrates how this occurs.

[00136] For certain clinical trials, particularly for comparing HPN-100 to PBA, HPN-100 will be administered at a dose that is equivalent (equimolar) to an amount of sodium PBA that would be considered suitable for the particular patient; and the dosage can then be adjusted by the methods described herein. For example, the HPN-100 dose range will match the PBA molar equivalent of the approved sodium PBA (sodium phenylbutyrate) (NaPBA) dose range. HPN-100 will be administered three times a day (TID) with meals. Note that the conversion of the dose of NaPBA to the dose of HPN-100 involves correction for their different chemical forms (i.e. HPN-100 consists of glycerol in ester linkage with 3 molecules of PBA and contains no sodium) ($\text{NaPBA [g]} \times 0.95 = \text{HPN-100 [g]}$) as well as correction for the specific gravity of HPN-100, which is 1.1 g/mL.

HPN-100 Dose Ranges Corresponding to Recommended Daily Doses of Sodium PBA

Sodium PBA	HPN-100 PBA Equivalent Dose (mg)	HPN-100 PBA Equivalent Dose (mL)
450-600 mg/kg/day (patients \leq 20 kg)	428 – 570 mg/kg/day	0.39-0.52 mL/kg/day
9.9-13.0 g/m ² /day (patients > 20 kg)	9.4 – 12.4 g/m ² /day	8.6-11.2 mL/m ² /day
Maximum Daily Dose: 20 g	Maximum Daily Dose: 19 g	17.4 mL

¹ 20 g of sodium PBA contains ~17.6 g of phenylbutyric acid; 19 g of HPN-100 contains ~17.6 g of phenylbutyric acid

Example 9

Determination of a Starting Dosage and Dose Adjustment of HPN-100

[00137] A patient having a nitrogen retention state (e.g. an inherited urea cycle disorder or cirrhosis) who is currently not being treated with an ammonia scavenging agent as described in this invention is determined clinically to be in need of such treatment. This clinical determination would be based upon a variety of factors (e.g. signs and symptoms of HE in patients with cirrhosis, elevated blood ammonia levels).

[00138]. The starting dosage is based on clinical considerations, including the estimation of residual urea synthetic capacity (an infant with UCD presenting with hyperammonia in the first few days of life would be presumed to have no significant urea synthesis capacity) and appropriate dietary protein intake (i.e., infants with UCD require increased dietary protein to support body growth, but long-term dietary protein restriction in patients with cirrhosis is usually ineffective or counterproductive, and the methodology outlined in this invention. For example, an adult with limited residual urea synthetic capacity is treated with an initial dosage of HPN-100 of 19 g per day and placed on a protein-limited diet containing about 25 g of protein per day. The patient's daily urinary output of PAGN is monitored. The daily intake of HPN-100 amounts to 19 g of HPN-100, at a molecular weight of ~530, which is 0.0358 mol HPN-100. Each mole of HPN-100 can theoretically be converted into three moles of PAA and thus three moles of PAGN, so the 19 g daily dosage of HPN-100 could produce 0.108 mol of PAGN in vivo. If entirely converted into PAGN and all of the PAGN is excreted in the urine, the theoretical quantity of PAGN would be 28.4 g per day, which would be sufficient to mediate the waste nitrogen excretion resulting from ~41 grams of dietary protein, assuming that 16% of dietary protein is nitrogen and ~47% of dietary nitrogen is excreted as waste nitrogen (see Brusilow).

[00139] However, as demonstrated herein, HPN-100 is typically converted into urinary PAGN with an efficiency of about 60% to 75% (typically about 60% conversion was found in UCD patients; conversion in cirrhotic patients was about 75%), thus the physician would expect to observe about 17 g of urinary PAGN output per day from this dosage of HPN-100. This corresponds to ~25 grams of dietary protein – which is similar to the prescribed amount, but less than the theoretical amount (41 grams) this dosage of HPN-100 might have been expected to account for theoretically. Thus the adjustment for 60-75% efficiency significantly affects the overall treatment program, and knowing what efficiency to expect enables the treating physician to avoid putting the patient on a diet containing too much protein for the patient to manage on this dosage of HPN-100.

[00140] When monitoring the patient, if the doctor observes a higher output of urinary PAGN than expected, the dosage of HPN-100 is reduced proportionally; thus if 21 g of urinary PAGN per day is observed, the physician will reduce the dosage of HPN-100 to $(17/21) * 19g = 15g$. Similarly, if urinary PAGN output is below that expected amount, such as 12 g per day, the amount of HPN-100 would be increased: if 12 g is observed and 17 is expected, the physician could adjust the HPN-100 dosage to $(17/12) * 19g = 27g$ HPN-100 per day, if that dosage is within a range

considered safe to administer to the patient. Either the dosage of HPN-100 or dietary protein intake could be adjusted to optimize the treatment plan for this subject.

[00141] Optionally, the urinary PAGN output may be determined as a ratio of urinary PAGN concentration to urinary creatinine concentration; creatinine levels are typically stable enough for a given individual to provide a normalization factor for urine volume so that rather than determining total daily urinary PAGN, the physician can estimate total daily urinary PAGN from testing a single urine sample.

[00142] The physician may also monitor the plasma ammonia levels and dietary protein intake in the patient to ascertain whether the patient's dietary protein intake and drug treatment combined are producing the appropriate therapeutic effect. Dietary protein intake or drug dosage or both could be adjusted to attain a normal or desired plasma ammonia level, e.g., a level below about 40 $\mu\text{mol/L}$. However, as demonstrated by the observations described herein, the physician would not use plasma levels of PAA or PBA to adjust the dosage of HPN-100 or otherwise guide treatment, as those levels do not correlate well with the ammonia scavenging effect of the administered HPN-100.

[00143] If the 19g dose of HPN-100 is determined to be inadequate (e.g. patient requires an increase in dietary protein which would result in excretion of waste nitrogen exceeding his or her urea synthesis capacity and PAGN excretion), HPN-100 dose would be increased sufficiently to cover the necessary dietary protein and the same methodology of dose adjustment based on urinary PAGN excretion would be applied to determine that dosage of HPN-100.

[00144] In a subject having little or no urea synthesis capacity where essentially all urinary nitrogen would be accounted for by PAGN, the ammonia scavenging effect may be monitored by determination of total urinary nitrogen (TUN), rather than directly measuring PAGN levels in the urine.

[00145] Optionally, the TUN can be used as a measure of urea synthesis capacity, by subtracting the amount of nitrogen present as PAGN.

Example 10

Determination of a Dosage of HPN-100 for a Patient already on sodium PBA

[00146] A patient with a UCD already on sodium PBA who is to be transitioned to HPN-100 would undergo assessment of dietary protein and measurement of urinary PAGN excretion.

[00147] If the patient is judged to be adequately controlled on sodium PBA , then the starting dose of HPN-100 would be the amount necessary to deliver the same amount of PAA (e.g. 19 grams of HPN-100 would correspond to 20 grams of sodium PBA). Subsequent dose adjustment would be based on repeated measurement of urinary PAGN as well as assessment of dietary protein and ammonia. , However, as demonstrated by the observations described herein, the physician would not use plasma levels of PAA or PBA either to determine the initial dosage of HPN-100 or adjust the dosage of HPN-100 or otherwise guide treatment, as those levels do not correlate well with the ammonia scavenging effect of the administered HPN-100.

[00148] If the patient is determined to be inadequately controlled on sodium PBA , then the starting dose of HPN-100 would be selected to deliver an amount of PAA higher than the dose of sodium PBA provided such HPN-100 dosage is otherwise appropriate. Subsequent dose adjustment would be based on repeated measurement of urinary PAGN as well as assessment of dietary protein and plasma ammonia. However, as demonstrated by the observations described herein, the physician would not use plasma levels of PAA or PBA either to determine the initial dosage of HPN-100 or adjust the dosage of HPN-100 or otherwise guide treatment, as those levels do not correlate well with the ammonia scavenging effect of the administered HPN-100.

[00149] Optionally, for example in a 'fragile' UCD patient with a history of repeated episodes of hyperammonemia, the conversion from sodium PBA to HPN-100 might occur in more than one step, whereby, at each step, the dose of sodium PBA would be reduced in an amount corresponding to the amount of PAA delivered by the incremental dose of HPN-100.

[00150] If the dose of HPN-100 is determined to be inadequate (e.g. patient requires an increase in dietary protein which would result in production of waste nitrogen exceeding his or her urea synthesis capacity and PAGN excretion), HPN-100 dose would be increased sufficiently to cover the necessary dietary protein and the same methodology of dose adjustment based on urinary PAGN excretion would be applied.

[00151] The examples set forth herein are illustrative only, and should not be viewed as limiting the invention.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL <small>(ONLY FOR NEW NONPROVISIONAL APPLICATIONS UNDER 37 CFR 1.53(B))</small>	Attorney Docket No.	643982000100
	First Inventor	Bruce SCHARSCHMIDT
	Title	METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS
	Express Mail Label No.	

APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents.</small>	ADDRESS TO: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450
1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) 2. <input type="checkbox"/> Applicant claims small entity status. <small>See 37 CFR 1.27.</small> 3. <input checked="" type="checkbox"/> Specification [Total Pages <u>60</u>] <small>Both the claims and abstract must start on a new page (For information on the preferred arrangement, see MPEP 608.01(a))</small> 4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets <u>15</u>] 5. Oath or Declaration [Total Sheets _____] a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> A copy from a prior application (37 CFR 1.63(d)) <small>(for continuation/divisional with Box 18 completed)</small> i. <input type="checkbox"/> DELETION OF INVENTOR(S) <small>Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</small> 6. <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 (2 pages) 7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) <input type="checkbox"/> Landscape Table on CD 8. Nucleotide and/or Amino Acid Sequence Submission <small>(if applicable, items a. – c. are required)</small> a. <input type="checkbox"/> Computer Readable Form (CRF) b. Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or ii. <input type="checkbox"/> Paper c. <input type="checkbox"/> Statements verifying identity of above copies	ACCOMPANYING APPLICATION PARTS 9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) Name of Assignee <div style="border: 1px solid black; height: 20px; width: 100%;"></div> 10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <small>(when there is an assignee)</small> 11. <input type="checkbox"/> English Translation Document (if applicable) 12. <input type="checkbox"/> Information Disclosure Statement (PTO/SB/08 or PTO-1449) <input type="checkbox"/> Copies of citations attached 13. <input type="checkbox"/> Preliminary Amendment 14. <input type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small> 15. <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small> 16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C.122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or equivalent. 17. <input type="checkbox"/> Other: <div style="border: 1px solid black; height: 40px; width: 100%;"></div>
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No.: _____ Prior application information: Examiner _____ Art Unit: _____	
19. CORRESPONDENCE ADDRESS	
<input checked="" type="checkbox"/> The address associated with Customer Number: <u>25225</u> OR <input type="checkbox"/> Correspondence address below	
Name	
Address	
City	State
Country	Telephone
Signature	/Michael G. Smith/
Name (Print/Type)	Michael G. Smith
Date	January 7, 2009
Registration No. (Attorney/Agent)	44,422



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

Table with 7 columns: APPLICATION NUMBER, FILING or 371(c) DATE, GRP ART UNIT, FIL FEE REC'D, ATTY,DOCKET.NO, TOT CLAIMS, IND CLAIMS. Row 1: 12/350,111, 01/07/2009, 1614, 1686, 643982000100, 29, 12

CONFIRMATION NO. 6290

25225
MORRISON & FOERSTER LLP
12531 HIGH BLUFF DRIVE
SUITE 100
SAN DIEGO, CA 92130-2040

FILING RECEIPT



Date Mailed: 01/27/2009

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Bruce SCHARSCHMIDT, South San Francisco, CA;

Power of Attorney: None

Domestic Priority data as claimed by applicant

This appln claims benefit of 61/093,234 08/29/2008
and claims benefit of 61/048,830 04/29/2008

Foreign Applications

If Required, Foreign Filing License Granted: 01/21/2009

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US 12/350,111

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

Table with 4 columns: APPLICATION NUMBER (12/350,111), FILING OR 371(C) DATE (01/07/2009), FIRST NAMED APPLICANT (Bruce SCHARSCHMIDT), ATTY. DOCKET NO./TITLE (643982000100)

CONFIRMATION NO. 6290

FORMALITIES LETTER



25225
MORRISON & FOERSTER LLP
12531 HIGH BLUFF DRIVE
SUITE 100
SAN DIEGO, CA 92130-2040

Date Mailed: 01/27/2009

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment.

- The oath or declaration is missing. A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required. Note: If a petition under 37 CFR 1.47 is being filed, an oath or declaration in compliance with 37 CFR 1.63 signed by all available joint inventors, or if no inventor is available by a party with sufficient proprietary interest, is required.

The applicant needs to satisfy supplemental fees problems indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.16(f) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this notice.

SUMMARY OF FEES DUE:

Total additional fee(s) required for this application is \$65 for a small entity

- \$65 Surcharge.

Replies should be mailed to:

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://portal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at **1-866-217-9197** or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

/wjsale/

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

Electronic Acknowledgement Receipt

EFS ID:	4851665
Application Number:	12350111
International Application Number:	
Confirmation Number:	6290
Title of Invention:	METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS
First Named Inventor/Applicant Name:	Bruce SCHARSCHMIDT
Customer Number:	25225
Filer:	Michael Glenn Smith/Jessica Conen
Filer Authorized By:	Michael Glenn Smith
Attorney Docket Number:	643982000100
Receipt Date:	24-FEB-2009
Filing Date:	07-JAN-2009
Time Stamp:	19:59:20
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$65
RAM confirmation Number	5987
Deposit Account	031952
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 917 (Patent application and reexamination processing fees)

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	643982000100TRANS.pdf	27459 160f800b70cffe647b08bd88a5444744ba301d6ef	no	1
Warnings:					
Information:					
2	Oath or Declaration filed	643982000100DEC.pdf	176168 8a0694cc9e4d9da333f1f76fe1f56d01c0057691	no	3
Warnings:					
Information:					
3	Information Disclosure Statement Letter	643982000100IDS.pdf	24039 4e72fe9c1f958b05b88497f2cbc2b625b4349c35	no	3
Warnings:					
Information:					
4	Information Disclosure Statement (IDS) Filed (SB/08)	643982000100SB08.pdf	31682 ad326e09909c986f0ff3b3994bb4f742151ead4	no	1
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
5	Foreign Reference	WO2006056794Jalan06012006.pdf	2594219 edc0bb3473b6fd92756447fc3593721ae2666850	no	61
Warnings:					
Information:					
6	NPL Documents	BRUSILOW1991PediatricRes147.pdf	187883 8788d304e8bd08dda274c3e0f3adcbdaf1fb83e	no	4
Warnings:					
Information:					
7	NPL Documents	CHANG2001PNASUSA9808.pdf	855444 73187ef9b8f94260f8aa8e1e9818934f51e7f21c	no	6
Warnings:					
Information:					
8	NPL Documents	FDALabel_BUPHENYL.pdf	558958 772d8da454b4f6caedee80e58fd2768cd23d22be	no	6
Warnings:					
Information:					

9	NPL Documents	KASUMOV2004DrugMetabDisp 10.pdf	1167314 7ee7cef36b54ad2745e955d678bca216b2 0bba0	no	10
Warnings:					
Information:					
10	NPL Documents	RUDMAN1973JCLinInvest2241. pdf	758124 f4a2a85766f5907951cc6189285b142fff60 b92	no	9
Warnings:					
Information:					
11	NPL Documents	SINGH2001SupplJPediatricsS1. pdf	303549 0dea51a0d56849361f6fe7f5f08e013eee0d 4d7	no	5
Warnings:					
Information:					
12	NPL Documents	THIBAUT1994CancerRes1690. pdf	1141364 413e4f7133cd39ca6c14b8e5a870fee52242 b239	no	5
Warnings:					
Information:					
13	NPL Documents	THIBAUT1995Cancer2932.pdf	1185711 62189db432e0059d97bbd0a4d90500338b 912ebd	no	7
Warnings:					
Information:					
14	NPL Documents	BERRY2001JPediatricsS56.pdf	675360 35cc0494e97b85eeb05cad70a7ec3b0b663 2a8fb	no	6
Warnings:					
Information:					
15	NPL Documents	BRUSILOW1993JMetabolism13 36.pdf	595958 d5d7a112529921e5ecc52458e4f580be8af6 39d9	no	4
Warnings:					
Information:					
16	NPL Documents	BRUSILOW1995ProgLivDis293. pdf	1285565 6890ff3a1101fb36d48c9d383963047d7555 3966	no	17
Warnings:					
Information:					
17	Fee Worksheet (PTO-06)	fee-info.pdf	30172 37af40d16be3c7786779cc59177385557db 60105	no	2
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Electronic Patent Application Fee Transmittal

Application Number:	12350111
Filing Date:	07-Jan-2009
Title of Invention:	METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS
First Named Inventor/Applicant Name:	Bruce SCHARSCHMIDT
Filer:	Michael Glenn Smith/Jessica Conen
Attorney Docket Number:	643982000100

Filed as Small Entity

Utility under 35 USC 111(a) Filing Fees

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Late filing fee for oath or declaration	2051	1	65	65

Petition:

Patent-Appeals-and-Interference:

Post-Allowance-and-Post-Issuance:

Extension-of-Time:

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
Miscellaneous:				
Total in USD (\$)				65

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 June 2006 (01.06.2006)

PCT

(10) International Publication Number
WO 2006/056794 A1

(51) International Patent Classification:
A61P 1/16 (2006.01) A61K 31/198 (2006.01)
A61K 31/192 (2006.01)

(74) Agents: **WOODS, Geoffrey, Corlett** et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5JJ (GB).

(21) International Application Number:
PCT/GB2005/004539

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
28 November 2005 (28.11.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0426141.8 26 November 2004 (26.11.2004) GB
0426142.6 26 November 2004 (26.11.2004) GB

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **UCL BIOMEDICA PLC** [GB/GB]; Finance Division, University College London, Gower Street, London WC1E 6BT (GB).

(72) Inventors; and

Published:

— *with international search report*

(75) Inventors/Applicants (*for US only*): **JALAN, Rajiv** [IN/GB]; 69-75 Chenies Mews, London WC1E 6HX (GB). **JALAN, Kamal, Nayan** [IN/IN]; 36 Shakespeare Sarani, 700017 Kolkata (IN).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS COMPRISING ORNITHINE AND PHENYLACETATE OR PHENYLBUTYRATE FOR TREATING HEPATIC ENCEPHALOPATHY

(57) Abstract: The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.



WO 2006/056794 A1

**COMPOSITIONS COMPRISING ORNITHINE AND PHENYLACETATE
OR PHENYLBUTYRATE FOR TREATING HEPATIC
ENCEPHALOPATHY**

Field of the invention

The present invention relates to the prevention or treatment of liver
5 decompensation or hepatic encephalopathy.

Background of the invention

Chronic liver disease is characterised by the gradual destruction of liver tissue
over time, whereby healthy and regenerating liver tissue is slowly replaced with scar
10 and necrotic tissue. This is known as liver cirrhosis. Normal liver function is impaired
and the scar tissue progressively diminishes blood flow through the liver. As normal
regenerating liver tissue is lost, nutrients, hormones, drugs and toxins are no longer
effectively processed.

This can result in symptoms including abnormal clearance of proteins absorbed
15 through the intestinal tract, leading to accumulation of ammonia; abnormal excretion,
leading to an accumulation of bilirubin in the blood, producing jaundice; increased
sinusoidal pressure, leading to fluid accumulation in the abdomen (ascites); and portal
hypertension (and portosystemic shunting) wherein scarred liver tissue acts as a barrier
to blood flow, leading to increased portal blood pressure and oesophageal varices.

20 Patients with chronic liver disease can be in a fairly stable clinical state and
exhibit few or no symptoms. However, such patients are at risk of an abrupt
deterioration in their condition which can lead to acute-on-chronic liver failure. This
transition from a “compensated” state, where the liver is able to function, albeit at a
reduced level, to a “decompensated” state, where liver function fails, involves the effect
25 of precipitating events. Precipitating events associated with chronic liver disease
include gastrointestinal bleeding, infection (sepsis), portal vein thrombosis and
dehydration.

For example, 50% of patients with cirrhosis of the liver have oesophageal
varices and in a third of these patients, the oesophageal varices will burst and cause
30 gastrointestinal bleeding within two years of diagnosis (Grace ND (1992) Gastroenterol
Clin North Am 21: 149-161). An upper gastrointestinal bleed is known to increase the
susceptibility to life-threatening complications such as bacterial peritonitis, sepsis, renal
failure and hepatic encephalopathy (Teran *et al.* (1997) Gastroenterology 112: 473-482;

Garden *et al.* (1985) *Br J Surg* 72: 91-95; Pauwels *et al.* (1996) *Hepatology* 24: 802-806; Bleichner *et al.* (1986) *Br J Surg* 73: 724-726) resulting in the death of about 30% of patients despite adequate control of bleeding (Grace 1992 *supra*).

Hepatic encephalopathy (HE) is a complex neuropsychiatric disorder that occurs
5 in diverse clinical situations such as acute or chronic liver disease and spontaneous portosystemic venous shunting. In the early stages of hepatic encephalopathy subtle mental changes occur such as poor concentration, confusion and disorientation. In severe cases, hepatic encephalopathy can lead to stupor, coma, brain swelling (cerebral edema) and death. In the case of patients who develop HE as a result of chronic liver
10 disease, the onset of HE is often the result of a clinically precipitating event such as gastrointestinal bleeding, sepsis (infection), portal vein thrombosis or dehydration.

Gastrointestinal bleeding and portosystemic shunting allows toxic substances, which are usually metabolised by the liver, to bypass the liver, enter the systemic circulation and cross the blood-brain barrier to exert direct or indirect neurotoxic effects
15 on the central nervous system. Ammonia accumulation is thought to play an important role in the progression of hepatic encephalopathy and multiorgan failure (respiratory failure, cardiovascular failure, kidney failure). In addition to ammonia, septicaemia (or bacterial peritonitis) which develops soon after a gastrointestinal bleed is also likely to be a contributing factor to hepatic encephalopathy.

20 Liver decompensation can then lead to multiorgan failure and hepatic encephalopathy. In the early stages of hepatic encephalopathy subtle mental changes such as poor concentration or the inability to construct simple objects occurs. In severe cases, hepatic encephalopathy can lead to stupor, coma, brain swelling and death.

The prognosis for patients with chronic liver disease is difficult to estimate
25 because the condition has many causes. Preventative measures to minimise progression from the compensated state to the decompensated state include avoidance of further causative agents which will worsen the condition, such as complete abstinence from alcohol and vaccination against hepatitis A and B.

However, once liver decompensation occurs, the chances of survival are reduced
30 and liver transplantation is the only treatment that can extend life. Since it is liver decompensation that leads to a reduced life expectancy, it is highly desirable to prevent liver decompensation from occurring.

A common therapy for patients with hepatic encephalopathy involves strategies to reduce the concentration of ammonia. These include restriction of dietary protein intake; administration of lactulose, neomycin, L-ornithine L-aspartate (LOLA), or sodium benzoate; and cleansing enemas.

5

Summary of the invention

- The present invention concerns the use of ornithine and at least one of phenylacetate and phenylbutyrate to prevent or treat liver decompensation or hepatic encephalopathy (HE) in patients. Isoleucine may also be administered to those patients further having an isoleucine deficiency attributable, for example to gastrointestinal bleeding. Accordingly, the invention provides:
- use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy;
 - 10 - use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy;
 - use of ornithine and at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for preventing or treating liver decompensation or hepatic
20 encephalopathy;
 - products containing ornithine and at least one of phenylacetate and phenylbutyrate for simultaneous, separate or sequential use for preventing or treating liver decompensation or hepatic encephalopathy;
 - a pharmaceutical composition comprising ornithine and at least one of
25 phenylacetate and phenylbutyrate;
 - an agent for preventing or treating liver decompensation or hepatic encephalopathy, comprising ornithine and at least one of phenylacetate and phenylbutyrate; and
 - a method of treating a patient having or at risk of having liver decompensation
30 or hepatic encephalopathy, which method comprises administering an effective amount of ornithine and at least one of phenylacetate and phenylbutyrate to said patient.

Brief description of the Figures

Figure 1 shows that neutrophil function is altered in patients with cirrhosis and worsens with increasing severity of liver disease.

Figure 2 shows that ammonia reduces neutrophil phagocytosis.

5 Figure 3 shows that ammonia reduces neutrophil chemotaxis.

Figure 4 shows that the effect of ammonia on neutrophil phagocytosis can be reversed by interventions.

Figure 5 shows that a simulated gastrointestinal bleed reduces neutrophil chemotaxis which can be partially reversed by administration of isoleucine.

10 Figure 6 shows that a simulated bleed reduces protein synthesis and stimulates isoleucine oxidation inappropriately.

Figure 7 shows that administration of isoleucine during a simulated bleed enhances protein synthesis but does not reduce ammonia concentration.

15 Figure 8 shows that administration with LOLA reduces ammonia concentration but allows ammonia to regenerate.

Figure 9 shows that active removal of glutamine prevents the secondary rise in ammonia concentration.

Figure 10 shows that phenylacetate binds glutamine to make an excretable compound and prevents the secondary rise in ammonia.

20 Figure 11 shows the effect of ornithine and phenylbutyrate on ammonia levels in patients with advanced cirrhosis.

Figure 12 shows the effect of ornithine and phenylbutyrate on glutamine levels in patients with advanced cirrhosis.

25 Figure 13 shows the changes in mental state of patients treated with placebo, O, P or O+P.

Figure 14 shows the effect of ornithine, phenylbutyrate and isoleucine on ammonia levels in patients with advanced cirrhosis.

Figure 15 shows the effect of ornithine, phenylbutyrate and isoleucine on glutamine levels in patients with advanced cirrhosis.

30 Figure 16 shows the effect of ornithine, phenylbutyrate and isoleucine on glycine levels in patients with advanced cirrhosis.

Figure 17 shows the effect of ornithine, phenylbutyrate and isoleucine on isoleucine levels in patients with advanced cirrhosis.

Figure 18 shows the effect of ornithine, phenylbutyrate and isoleucine on ornithine levels in patients with advanced cirrhosis.

Figure 19 shows the effect of ornithine and phenylbutyrate on arterial ammonia in the bile duct ligated rat model.

5 Figure 20 shows the effect of ornithine and phenylbutyrate on plasma ornithine in the bile duct ligated rat model.

Figure 21 shows the effect of ornithine, phenylbutyrate and isoleucine on arterial plasma ammonia levels in a hyperammonaemic acute liver failure rat model.

10 Figure 22 shows muted arterial ammonia increase in the devascularized pig model of acute liver failure with OP treatment.

Figure 23 shows that ammonia is being taken from the blood by the muscle in the O and the OP treated animals (samples were taken from the femoral vein –artery). In contrast, the placebo and the P alone animals shows an increase in ammonia production by the muscle.

15 Figure 24 shows that ammonia is produced by the gut in all animals except the OP treated animal (samples were taken from the portal drained viscera –artery).

Figure 25 shows that muscle glutamine release is increased by O but not P used in isolation. OP caused a markedly greater release of muscle glutamine (thereby trapping ammonia as glutamine in the muscle).

20 Figure 26 shows that gut glutamine uptake is enhanced by O, but reduced by OP (thereby reduced generation of ammonia in the gut).

Figure 27 shows that arterial ornithine levels increase in the two animals (O alone and OP groups) to which it is administered.

Figure 28 shows that arterial glutamine levels rise with O, but less so with OP.

25 Figure 29 shows that the combination of OP prevents the increase in the ammoniagenic amino acid glycine.

Figure 30 shows that ornithine alone caused an increase in brain water, phenyl acetate induced a small reduction in brain water, while in combination these agents bring about a substantial reduction in brain water (% control).

30

Detailed description of the invention

Throughout the present specification and the accompanying claims the words "comprise" and "include" and variations such as "comprises", "comprising", "includes"

and "including" are to be interpreted inclusively. That is, these words are intended to convey the possible inclusion of other elements or integers not specifically recited, where the context allows.

The present invention is concerned with the early treatment of patients with liver disease, before development of liver decompensation and thus before hepatic encephalopathy has occurred, to prevent or delay the onset of liver decompensation. Alternatively, the present invention is concerned with treatment of hepatic encephalopathy by effectively reducing ammonia concentration and maintaining neutrophil function.

10

Subjects to be treated

The present invention is concerned with the prevention or treatment of liver decompensation or hepatic encephalopathy. The subject's liver may therefore be in the compensated state. The subject may have chronic liver disease. The subject may have liver cirrhosis. The subject may have acute liver failure. The subject to be treated may have hepatic encephalopathy.

15

The onset of both acute and chronic liver disease may be due to a xenobiotic cause. For example, the subject may have been exposed to a chemical, drug or some other agent which causes liver damage. The subject may have a reaction to an over-the-counter, prescriptive or "recreational" drug which causes liver damage. The subject may have been taking RezulinTM (troglitazone; Parke-Davis), SerzoneTM (nefazodone; Bristol-Myers Squibb) or other drugs thought to cause liver damage. The subject may be one who has had an overdose of a particular drug or exceeded the recommended dosage of a drug capable of causing liver damage. For example, the subject may have taken an overdose of paracetamol. The subject may have been exposed to chemicals which can cause liver damage such as, for example, at their place of work. For example, the subject may have been exposed to such chemicals in an industrial or agricultural context. The subject may have consumed plants which contain compounds which can cause liver damage, in particular this may be the case where the subject is an animal, such as a herbivore. For example, the subject may have consumed a plant containing pyrrolizidine alkaloid such as ragwort. The subject may have been exposed to environmental toxins thought to cause liver disease.

20

25

30

Drug-related liver toxicity comprises more than 50% of all cases with acute liver disease (acute liver failure). Acetaminophen-(also known as paracetamol and *N*-acetyl-p-aminophenol) toxicity is the most common cause of acute liver failure in the United States and Great Britain. Long-term moderate to heavy alcohol users who take
5 acetaminophen in therapeutic or modestly excessive doses are at risk of severe hepatic injury and possibly acute liver failure. Alcohol use potentiates the toxic effects of acetaminophen. Idiosyncratic drug toxicity also contributes to acute liver failure. Idiosyncratic drug toxicity is thought to be a hypersensitivity response wherein the subject responds to a drug in a pharmacologically abnormal way. This abnormal
10 response can lead to acute liver failure.

The acute liver failure or chronic liver disease may be caused by infection with a pathogenic organism. For example, the liver disease may be due to viral infection. In particular, the subject may be infected, or have been infected, with a virus which causes hepatitis. The subject may have chronic viral hepatitis. The virus may, for example, be
15 hepatitis B, C or D virus. In some cases, and in particular where the subject has viral hepatitis, the subject may also be infected with HIV-I or II. The subject may have AIDS. It is possible that the subject may have been, or be, infected with other organisms which cause liver disease and in particular those which are present in the liver during some stage of their life cycle. For example, the subject may have, or have
20 had, liver fluke.

The subject may have an inherited disease which causes, or increases the risk of, chronic liver disease. For example, the subject may have one or more of hepatic hemochromatosis, Wilson's disease or α -1-antitrypsin deficiency. The subject may have an inherited disorder which causes some kind of structural or functional abnormality in
25 the liver which increases the likelihood of liver fibrosis. The subject may be genetically predisposed to develop an autoimmune disorder which damages the liver and hence which can contribute to liver fibrosis.

The chronic liver disease may be alcohol-induced. A man or woman to be treated may be, or have been, an alcoholic. He or she may be, or have been, consuming
30 on average 50 or more units of alcohol per week, 60 or more units of alcohol per week, 75 or more units of alcohol per week and even 100 or more units of alcohol per week. The man or woman may be, or have been, consuming on average up to 100 units of alcohol per week, up to 150 units of alcohol per week and even up to 200 units of

alcohol per week. The measurement of one unit of alcohol differs from country to country. Here, one unit equals 8 grams of ethanol in accordance with the United Kingdom standard.

5 The man or woman may have been consuming such levels of alcohol for 5 or more years, 10 or more years, 15 or more years or 20 or more years. The subject may have been consuming such levels of alcohol for up to 10 years, up to 20 years, up to 30 years and even up to 40 years. In cases of alcohol-induced liver cirrhosis the subject may be aged, for example, 25 years or over, 35 years or over, 45 years or over and even over 60 years.

10 The subject may be male or female. Women may be more susceptible to the adverse effects of alcohol than men. Women can develop alcoholic chronic liver disease in a shorter time frame and from smaller amounts of alcohol than men. There seems to be no single factor to account for increased susceptibility to alcoholic liver damage in females, but the effect of hormones on the metabolism of alcohol may play an important
15 role.

In other embodiments of the invention, the subject may have one or more of a number of other conditions known to result in liver damage such as, for example, primary biliary cirrhosis, autoimmune chronic active hepatitis, and/or schistosomiasis (parasitic infection). The subject may have or have had a bile duct blockage. In some
20 cases, the underlying cause of chronic liver disease may not be known. For example the subject may have been diagnosed as having cryptogenic cirrhosis. In one embodiment, the subject may be suspected of having any of the conditions listed herein.

Methods for diagnosing chronic liver disease, acute liver failure and hepatic encephalopathy are well known in the art and in particular to clinicians and
25 veterinarians in the field. Preferably, the subject will have been diagnosed as having a liver disease and hepatic encephalopathy, for example by a medical or veterinarian professional. The subject may display one or more symptoms associated with liver disease such as one or more of jaundice, ascites, skin changes, fluid retention, nail changes, easy bruising, nose bleeds, oesophageal varices, and in male subjects may have
30 enlargement of breasts. The subject may display exhaustion, fatigue, loss of appetite, nausea, weakness and/or weight loss. The subject may also display one or more symptoms associated with hepatic encephalopathy such as one or more of confusion, disorientation, dementia, stupor, coma, cerebral edema, multiorgan failure (respiratory

failure, cardiovascular failure or kidney failure), muscle stiffness/rigidity, seizures or speech impairment. The subject to be treated may or may not be taking other drugs to treat liver disease. The subject to be treated may be at risk of developing hepatic encephalopathy.

5 The liver disease may have been, or be, confirmed by physical examination including techniques such as ultrasound. Liver biopsies may have been taken to look for build up of fibrosis, necrotic cells, cellular degeneration and/or inflammation and other characteristic features of liver disease. Liver function may have been assessed in the subject to determine whether this is compromised in the subject. The nature and
10 underlying cause of the liver disease may be characterized. Any history of exposure to causative agents of liver disease may be determined.

 The subject to be treated may be at risk for hepatic encephalopathic episodes, for example patients who are awaiting liver transplants, surgical and/or portal hypertension patients. A person at risk for hepatic encephalopathic episodes is a person who has not
15 suffered any hepatic encephalopathic episodes or has not suffered any hepatic encephalopathic episode for an extended period of time (about 12 weeks or longer), but has a disorder or medical condition which creates a risk of hepatic encephalopathic episodes. A hepatic encephalopathic episode is a clinical condition characterised by the presence of cerebral dysfunction in patients with liver disease or dysfunction. There is a
20 wide spectrum of mental disturbances in hepatic encephalopathy which range from minimal where the main effects are a reduction in the quality of life, to overt which leads to coma and ultimately death.

 Scoring systems may be used to assess the severity of liver disease and hepatic encephalopathy and also the prognosis of subjects. The Child-Pugh, West Haven
25 Criteria, Glasgow Coma Scale or modified Child-Pugh scoring system may be used. Alternatively, the (APACHE) II scoring system may be used. Points are assigned to parameters including serum bilirubin levels, serum albumin levels and to signs including presence of ascites or encephalopathy. Subjects to be treated may be classified in Child-Pugh class A , B or C. Generally subjects to be treated are classified in Child-
30 Pugh class C.

 A man or woman to be treated may be aged, for example from 25 to 80 years. In one embodiment, the man or woman is aged from 45 to 70 years. In another

embodiment, the man or woman is aged from 25 to 44 years. In a further embodiment, the man or woman is aged over 65 years.

The invention does have veterinary use, however. The subject to be treated may be a farm animal for example, a cow or bull, sheep, pig, ox, goat or horse or may be a domestic animal such as a dog or cat. The subject may or may not be an animal model for liver disease. The animal may be any age, but will often be a mature adult subject.

Formulation

The amino acids used in the present invention may be pure crystalline amino acids. In general, the amino acids are in the L-form, rather than the D-form, or a mixture of D and L. Isolated forms of the amino acids are typically used. Any active form of the amino acid may be used to prevent or treat the liver decompensation or hepatic encephalopathy. A pharmaceutically acceptable form of the amino acid may be used. The amino acids may be employed as free amino acids or amino acid salts or derivatives.

Ornithine may be in pure crystalline amino acid form. In general, ornithine is in the L-form, rather than the D-form, or a mixture of D and L. Isolated forms of ornithine are typically used. Any active form of ornithine may be used or a pharmaceutically acceptable form of ornithine may be used. Ornithine may be employed as a free amino acid or an amino acid salt or derivative.

Typically, ornithine is used as a single, monomeric amino acid. Ornithine may be used in salt form, for example ornithine hydrochloride may be used. Ornithine may be in the form of a physiologically acceptable salt in free form. Therefore, the ornithine or the ornithine salt are typically not chemically bound, or covalently linked to any other agent.

Derivatives of ornithine may be used. For example, keto or hydroxy analogs of ornithine may be administered as sodium or calcium salts. Keto acids of ornithine include ornithine ketoglutarate, ornithine ketoleucine and ornithine ketovaline. Salts or derivatives of ornithine may be used in place of or in addition to free ornithine.

At least one of phenylacetate and phenylbutyrate may be used. Phenylacetate and/or phenylbutyrate may be in physiologically acceptable salt form, such as an alkali metal or alkaline earth metal salt. The salt may be sodium phenylacetate or sodium phenylbutyrate. The salt form of phenylacetate and phenylbutyrate may be in free form.

Therefore the phenylacetate and phenylbutyrate or phenylacetate salt and phenylbutyrate salt are typically not chemically bound, or covalently linked to any other agent.

Optionally isoleucine is used. Isoleucine may be in pure crystalline amino acid form. In general, isoleucine is in the L-form, rather than the D-form, or a mixture of D and L. Isolated forms of isoleucine are typically used. Any active form of isoleucine may be used or a pharmaceutically acceptable form of isoleucine may be used. Isoleucine may be employed as a free amino acid or an amino acid salt or derivative.

Typically, isoleucine is used as a single, monomeric amino acid. Isoleucine may be used in salt form, for example isoleucine hydrochloride may be used. Isoleucine may be in the form of a physiologically acceptable salt in free form. Therefore, the isoleucine or the isoleucine salt are typically not chemically bound, or covalently linked to any other agent.

15 *Pharmaceutical compositions*

The ornithine and the phenylacetate and/or phenylbutyrate are typically formulated for administration with a pharmaceutically acceptable carrier or diluent. The ornithine and the phenylacetate and/or phenylbutyrate may thus be formulated as a medicament with a standard pharmaceutically acceptable carrier(s) and/or excipient(s) as is routine in the pharmaceutical art. The exact nature of the formulation will depend upon several factors including the desired route of administration. Typically, ornithine and the phenylacetate and/or phenylbutyrate are formulated for oral, intravenous, intragastric, intravascular or intraperitoneal administration.

The pharmaceutical carrier or diluent may be, for example, an isotonic solution such as physiological saline. Solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, gum arabic, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known

manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film-coating processes.

Liquid dispersions for oral administration may be syrups, emulsions or suspensions. The syrups may contain as carriers, for example, saccharose or saccharose
5 with glycerine and/or mannitol and/or sorbitol.

Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain,
10 together with ornithine and at least one of phenylacetate and phenylbutyrate, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

Medicaments of the invention can comprise ornithine as the only amino acid component. Medicaments of the invention can comprise ornithine and isoleucine as the only amino acid components. The medicament may consist essentially of ornithine and
15 at least one of phenylacetate and phenylbutyrate. The medicament may consist essentially of ornithine, isoleucine and at least one of phenylacetate and phenylbutyrate.

The medicament may consist essentially of ornithine, phenylacetate and/or phenylbutyrate and a pharmaceutically acceptable carrier. Such a medicament therefore contains substantially no other amino acid in addition to ornithine. The medicament
20 may consist essentially of ornithine, isoleucine, phenylacetate and/or phenylbutyrate and a pharmaceutically acceptable carrier. Such a medicament therefore contains substantially no other amino acid in addition to ornithine and isoleucine.

The phenylacetate may be present in an amount from 5 to 100%, for example from 10 to 50%, or 20 to 40%, by weight of the weight of ornithine. The phenylbutyrate
25 may be present in an amount from 5 to 100%, for example from 10 to 50%, or 20 to 40%, by weight of the weight of ornithine.

However, the medicament may comprise free aspartate, glutamate or arginine in non-peptide form, typically in an insubstantial amount. Generally, the amount by weight of aspartate, glutamate or arginine does not exceed the amount by weight of ornithine.
30 By an insubstantial amount, it is meant that the amount by weight of aspartate, glutamate or arginine, or a combination of these amino acids, does not exceed 20% by weight of ornithine. Therefore, the medicament may comprise substantially no aspartate. In one embodiment, the composition does not comprise aspartate, glutamate

or arginine. Trace amounts of aspartate, glutamate or arginine may be present in the composition. By trace amount, it is meant that the amount by weight of aspartate, glutamate or arginine, or a combination of these amino acids, does not exceed 1% by weight of ornithine. Preferably, the amount by weight of aspartate, glutamate or arginine does not exceed 0.5% by weight of ornithine.

In another embodiment, the composition may comprise yet other amino acids in non-peptide form, typically as the free amino acid or a physiologically acceptable salt thereof in free form. The amount of these other amino acids generally does not exceed the amount by weight of ornithine. For example, the other amino acids may be present in an amount by weight up to 20%, for example from 5 to 20%, of the weight of ornithine. Such other amino acids that may be present in the composition include essential and non-essential amino acids. The composition may comprise other branched chain amino acids (BCAAs). BCAAs include isoleucine, valine and leucine. Thus, a composition of the invention may further comprise isoleucine and/or valine and/or leucine.

Treatment

Ornithine and at least one of phenylacetate and phenylbutyrate are administered in combination to a subject for preventing or delaying the onset of liver decompensation or hepatic encephalopathy. Ornithine and at least one of phenylacetate and phenylbutyrate can thus be administered in combination to improve the condition of a subject, for example a subject suffering from chronic liver disease following a precipitating event. Ornithine and at least one of phenylacetate and phenylbutyrate may be administered in combination to alleviate the symptoms of a subject, for example the symptoms associated with chronic liver disease in a subject following a precipitating event. Ornithine and at least one of phenylacetate and phenylbutyrate may be administered in combination to combat or delay the onset of liver decompensation or hepatic encephalopathy.

Ornithine and at least one of phenylacetate and phenylbutyrate may be administered in combination to a subject for treatment of hepatic encephalopathy. Ornithine and at least one of phenylacetate and phenylbutyrate may be administered in combination to improve the condition of a patient suffering from hepatic encephalopathy. Ornithine and at least one of phenylacetate and phenylbutyrate may be

administered in combination to alleviate the symptoms associated with hepatic encephalopathy. Ornithine and at least one of phenylacetate and phenylbutyrate may be administered in combination to combat hepatic encephalopathy. Ornithine and at least one of phenylacetate and phenylbutyrate may be administered in combination to prevent an initial hepatic encephalopathic episode in a person at risk of for hepatic encephalopathic episodes. Ornithine and at least one of phenylacetate and phenylbutyrate may be administered in combination lessen the severity of an initial hepatic encephalopathic episode in a person at risk of for hepatic encephalopathic episodes. Ornithine and at least one of phenylacetate and phenylbutyrate may be administered in combination to delay an initial hepatic encephalopathic episode in a person at risk of for hepatic encephalopathic episodes.

Development of liver decompensation and hepatic encephalopathy involves “precipitating events” (or “acute attacks”). Such precipitating events include gastrointestinal bleeding, infection (sepsis), portal vein thrombosis and dehydration. The onset of such an acute attack is likely to lead to hospitalisation. The patient may suffer one of these acute attacks or a combination of these acute attacks.

A subject who has had or is suspected of having had an acute attack is treated according to the invention with ornithine and phenylacetate and/or phenylbutyrate in combination to prevent progression of the liver to the decompensated state. The invention can therefore prevent the medical consequences of liver decompensation such as hepatic encephalopathy. The ornithine and phenylacetate and/or phenylbutyrate may be used to preserve liver function. Use of ornithine and phenylacetate and/or phenylbutyrate may thus extend the life of a patient with liver disease. In one embodiment, the metabolic consequences of a gastrointestinal bleed such as hyperammonemia, hypoisoleucemia and reduced protein synthesis in the post-bleeding period are prevented.

Typically, treatment of subjects may begin as soon as possible after the onset or the suspected onset of a precipitating event (acute attack). Preferably, treatment of the subject begins prior to repeated acute attacks. More preferably, treatment of the subject begins following the first acute attack.

Treatment is typically given promptly after the start of an acute attack. Treatment may begin after the symptom(s) of an acute attack or suspected acute attack have been detected e.g. by a medic such as a physician, a paramedic or a nurse.

Treatment may begin upon hospitalisation of the subject. Treatment may thus begin within 6 hours, within 3 hours, within 2 hours or within 1 hour after the symptom(s) of an acute attack or suspected acute attack have been detected. Treatment of the subject may therefore begin from 1 to 48 hours, for example from 1 to 36 hours or from 1 to 24
5 hours after the symptom(s) of an acute attack or suspected acute attack have been detected.

Treatment may occur for up to 8 weeks, for example up to 6 weeks, up to 4 weeks or up to 2 weeks after the symptom(s) of an acute attack or suspected acute attack have been detected. Treatment may therefore occur for up to 48 hours, for example for
10 up to 36 hours or for up to 24 hours after the symptom(s) of an acute attack or suspected acute attack have been detected. Typically, treatment occurs to the time when recovery from the acute precipitating event is evident.

The subject is treated with the ornithine and the phenylacetate and/or phenylbutyrate. Ornithine and at least one of phenylacetate and phenylbutyrate may be
15 administered in combination in a single medicament, or separately in two or three different medicaments. Where ornithine and at least one of phenylacetate and phenylbutyrate are to be administered in a combined medicament, the combination may be prepared immediately before administration, or may be stored as a combined medicament.

20 Where the ornithine and the phenylacetate and/or phenylbutyrate are to be administered separately, the medicaments may be administered simultaneously or sequentially over a period of time. Two or three separate medicaments may be administered over a period of time.

Where two medicaments are administered, ornithine may be administered first,
25 followed by administration of the phenylacetate and phenylbutyrate, the phenylacetate or the phenylbutyrate. Alternatively, the phenylacetate and phenylbutyrate, the phenylacetate or the phenylbutyrate may be administered first, followed by ornithine. In another embodiment, a combination of ornithine and phenylacetate may be administered first, followed by administration of phenylbutyrate. Alternatively, a combination of
30 ornithine and phenylbutyrate may be administered first, followed by administration of phenylacetate. In another embodiment, phenylacetate may be administered first, followed by administration of a combination of ornithine and phenylbutyrate.

Alternatively, phenylbutyrate may be administered first, followed by administration of a combination of ornithine and phenylacetate.

Where three medicaments are administered, ornithine, phenylacetate and phenylbutyrate are administered at separate times. Ornithine may be administered first, second or third. Where ornithine is administered first, phenylacetate or phenylbutyrate may be administered second, followed by administration of phenylbutyrate or phenylacetate. Where ornithine is administered second, phenylacetate or phenylbutyrate are administered first, and phenylbutyrate or phenylacetate are administered third. Where ornithine is administered third, phenylacetate or phenylbutyrate are administered first, and phenylbutyrate or phenylacetate are administered second.

The second medicament may be administered up to 5 hours, such as up to 2 hours or up to 1 hour, following administration of the first medicament. The second medicament can thus be administered from 15 minutes to 5 hours, for example from 30 minutes to 4 hours or from 1 hour to 3 hours, following administration of the first medicament.

The third medicament may be administered up to 5 hours, such as up to 2 hours or up to 1 hour, following administration of the second medicament. The third medicament can thus be administered from 15 minutes to 5 hours, for example from 30 minutes to 4 hours or from 1 hour to 3 hours, following administration of the second medicament.

The medicaments of the invention may be administered at the same site or at different sites. The medicaments of the invention may be administered via the same route or by different routes. A medicament of the invention may be administered by any suitable route. Preferably it is administered by oral, intravenous, intragastric, intraperitoneal or intravasular routes. For example, when ornithine and at least one of phenylacetate and phenylbutyrate are administered separately, they may all be administered orally or they may all be administered intravenously or ornithine may be administered orally and the phenylacetate and/or phenylbutyrate may be administered intravenously, or the phenylacetate and/or phenylbutyrate may be administered orally and ornithine may be administered intravenously.

Therapeutically effective amounts of ornithine, the phenylacetate and/or phenylbutyrate and the optional isoleucine are administered to the subject. The doses of the ornithine, the phenylacetate and/or phenylbutyrate and the isoleucine can be

determined according to various parameters such as the age, weight and condition of the subject to be treated; the type and severity of the liver disease; the route of administration; and the required regimen.

A typical dose of ornithine, of phenylacetate or phenylbutyrate, or of isoleucine is from 0.02 to 1.25, for example from 0.1 to 0.5, g per kg of body weight, depending on such parameters. Consequently, a dosage of ornithine, of phenylacetate or phenylbutyrate, or of isoleucine may be from 1 g to 50 g such as from 5 g to 30 g. The dosage of ornithine may be 10 to 30 g. The dose of isoleucine may be 5 to 15 g. The ornithine and phenylacetate / phenylbutyrate may be administered in a weight ratio from 10:1 to 1:10 such as from 5:1 to 1:5 or from 2:1 to 1:2 or about 1:1. A physician will be able to determine the required dosage of ornithine and of phenylacetate or phenylbutyrate and of the optional isoleucine for any particular subject.

A single dose of ornithine and a single dose of phenylacetate and/or phenylbutyrate may be administered. Optionally, a single dose of isoleucine may also be administered. Alternatively multiple doses, for example two, three, four or five doses, of ornithine and/or of the phenylacetate and/or phenylbutyrate and/or of the optional isoleucine may be administered. Such multiple doses may be administered over a period of one month or two weeks or one week. In another embodiment, a single dose or multiple doses such as two, three, four or five doses of ornithine and/or of phenylacetate and/or phenylbutyrate may be administered daily.

Other amino acids may be administered to a subject as noted above. The or each such other amino acid may be administered in the same medicament as the ornithine and/or the phenylacetate and/or phenylbutyrate, or may be administered separately. When administered separately, the or each other amino acid may be given simultaneously with, or at a different time such as up to 5 hours, up to 2 hours or up to 1 hour before or after, the administration of ornithine and/or phenylacetate and/or phenylbutyrate. The or each other amino acid is typically administered orally or intravenously.

A therapeutically effective amount of the or each other amino acid is administered to the subject. The dose will be dependent upon various parameters such as those noted above for ornithine, phenylacetate and phenylbutyrate. A typical dose of the or each other amino acid is from 0.02 to 1.25, for example from 0.1 to 0.5, g per kg

of bodyweight. A dosage of the or each other amino acid may therefore be from 1 g to 50 g such as 5 g to 30 g.

A single dose of the or each other amino acid may be administered. Alternatively, multiple doses, for example two, three, four or five doses may be administered. Such multiple doses may be administered over a period of one month or two weeks or one week. In another embodiment, a single dose or multiple doses such as two, three, four or five doses may be administered daily.

The following Examples illustrate the invention.

10

Example 1: Neutrophil function is altered in patients with cirrhosis and worsens with increasing severity of liver disease

Methods for Measurement of Neutrophil Phagocytosis and oxidative burst

15 *Phagotest:* Heparinised whole blood was incubated with opsonised FITC-labelled *E coli* and CD16. The cells were then analysed by flow cytometry (FACScan Becton Dickinson), gated through forward and side scatter and subsequently assessed on the basis of R-phycoerythrin (PE) [Immunotech, Marseille, France] fluochrome expression to identify CD16 positive cells. The gated population was then assessed for the presence of FITC-labelled bacteria.

20 *Phagoburst:* Heparinised whole blood was incubated with opsonised *E coli* suspension to stimulate oxidative burst. A substrate solution was added to determine the conversion of dihydrorhodamine (DHR) 123 to the fluorogenic compound Rhodamine (R) 123. The reaction was stopped and fixed before incubation with CD16 antibody for positive neutrophil identification. Analysis was then undertaken by flow cytometry.

25 *Neutrophil Chemotaxis:* Neutrophil chemotaxis was measured using a modified Boyden chamber method using interleukin-8 as chemo-attractant to stimulate chemokinesis.

30 **Patients and Methods**

We studied 30 patients with cirrhosis (Alcoholic cirrhosis; mean age 53.2 (SEM 4.6) and 20 healthy volunteers. Patients with cirrhosis were classified as those with superimposed alcoholic hepatitis (AH+) and those with decompensated or compensated

livers. Phagotest was used to determine the phagocytic capacity and Phagoburst was used to determine whether the cells were able to generate oxidative burst when exposed to *E coli*.

5 **Results**

We observed that neutrophils from cirrhotic patients had a significantly reduced ability to phagocytose bacteria. We also found that patients with cirrhosis had a reduced capacity to respond to stimulation of the neutrophils by *E coli* in terms of increasing the rate of generation of oxidative burst (Figure 1). This reduction in capacity correlated
10 with the severity of liver disease indicating that the more advanced the stage of liver disease, the less the ability to respond to and cope with infection.

Example 2: Ammonia reduces phagocytic capacity in neutrophils

15 **Methods for Measurement of Neutrophil Phagocytosis and oxidative burst**

As in Example 1.

Patients and methods

Blood was collected from healthy volunteers (n=15) and incubated for 1 hour
20 with increasing concentrations of ammonia. The ability of the neutrophils to phagocytose bacteria was measured using the Phagotest and Neutrophil chemotaxis assays. 10ng/ml IL-8 was used in the Neutrophil chemotaxis assay.

Results

25 With incubation of increasing concentrations of ammonia, there was a significant reduction in neutrophil phagocytosis (Figure 2) and also in neutrophil chemotaxis (Figure 3).

Example 3: The effect of ammonia on neutrophil phagocytosis can be reversed 30 by interventions

Methods for Measurement of Neutrophil Phagocytosis and oxidative burst

As in Example 1.

Patients and methods

Blood was collected from healthy volunteers (n=15) and incubated for 1 hour with ammonia and selected amino acids. The ability of the neutrophils to phagocytose bacteria was measured using the Phagotest assay.

Results

We observed that the ammonia-induced reduction in neutrophil phagocytosis could be partially reversed by ornithine and glutamine (Figure 4). However, neutrophil phagocytosis was made worse by co-incubation of ammonia with aspartate, but remained unchanged with L-ornithine L-aspartate.

Example 4: A simulated gastrointestinal bleed reduces neutrophil chemotaxis which can be partially reversed by administration of isoleucine

Methods

Ten overnight fasted, metabolically stable patients with biopsy proven cirrhosis of the liver [9 males and 1 female; mean 49.6 years (SEM 9.1); mean Child-Pugh score of 7.8 (SEM 1.2)] were studied prior to and two hours after an oral administration of 75 grams of an amino acid mixture that mimics the hemoglobin molecule (Nutricia, Cuijk, Netherlands). In seven other patients [4 male and 3 female; mean 51.4 years (SEM 6.7); mean Child-Pugh score of 8.1 (SEM 1.4)], following administration of the amino acid mixture, isoleucine was administered intravenously over a 2 hour period (iso-osmotic solution containing 40mg/l of isoleucine at a rate of 100 ml/hr). Neutrophil chemotaxis (see Example 1 for method) and plasma ammonia were measured in peripheral venous blood samples.

Results

Neutrophil chemotaxis was significantly lower in these cirrhotic patients compared with age-matched controls (53.3 SEM 4.6) and was significantly reduced after simulated bleeding from 31 (± 4.2) to 8 (± 5.4) cells/high power field ($p < 0.0001$) (Figure 5). Plasma concentration of ammonia increased significantly from 75.1 (± 4.2) to 124 (± 8.5) ($p < 0.001$). The change in the concentration of ammonia correlated with the

change in neutrophil chemotaxis ($r=0.65$ and $p < 0.05$). The reduction in neutrophil chemotaxis observed with the simulated bleed was abrogated in the group of patients treated with isoleucine $25.4 (\pm 6.0)$ cells/high power field.

5 **Example 5: A simulated bleed reduces protein synthesis and stimulates isoleucine oxidation inappropriately**

Methods

Five overnight fasted patients with cirrhosis of the liver were recruited. A blood
10 sample was collected and expired air was sampled before the start of the infusion of the stable isotopes for the measurement of background isotope enrichment. Then the patients received a primed continuous intravenous infusion of [$1-^{13}\text{C}$]-isoleucine (1 mg/kg bw/h) until the end of the experiment (t=480 min).

15 **Results**

Figure 6 shows average whole body rate of appearance of isoleucine (Wb Ra) and isoleucine oxidation during the last hour of saline (black bars) and amino acid (grey bars) infusion (values in mean \pm SEM; # represents $p < 0.05$). An upper GI bleed in patients with cirrhosis resulted in a reduction in isoleucine and markedly decreased
20 whole body protein synthesis. The fraction of isoleucine flux used for oxidation did not change after the simulated bleed despite the marked reduction in isoleucine concentration, pointing to occurrence of BCAA antagonism.

25 **Example 6: Administration of isoleucine during a simulated bleed enhances protein synthesis but does not reduce ammonia concentration**

Methods

Sixteen metabolically stable patients with biopsy-proven cirrhosis of the liver were studied. Patients were randomized either to supplementation with isoleucine
30 (40mg/L solution; 50 ml/hr) or placebo during a simulated bleed over a 4-hour period. Protein synthesis (measured using primed continuous infusion of L-[ring- $^2\text{H}_5$]phenylalanine), L-[ring- $^2\text{H}_4$]tyrosine and L-[ring- $^2\text{H}_2$]tyrosine) and ammonia.

Results

The results showed that infusion of isoleucine during a simulated bleed in patients with cirrhosis of the liver restores impaired protein synthesis of liver and muscle leading to a net anabolic state in these organs (Table 1). Ammonia concentration increased significantly in both groups but was not significantly different between those administered with isoleucine or placebo (Figure 7).

10 Example 7: Aspartate accumulation following infusion of L-ornithine L- aspartate in patients with advanced cirrhosis

Methods

5 patients with advanced cirrhosis who were awaiting liver transplantation (age: 59; 3 male, Child Class C disease, severe ascites, creatinine 102 $\mu\text{mol/L}$) were undergoing treatment with 40 g/day of L-ornithine L-aspartate.

Results

Over a 3 day period there was a significant and progressive increase in the aspartate concentration increasing to 5 times the basal value (Table 2).

20

Table 2

	PRE	Day 1	Day 2	Day 3
ASPARTATE ($\mu\text{mol/L}$)	72 (11.8)	178 (23.2)	289 (27.1)	354 (31.1)

Table 1
Protein kinetics determined using the Phe model at t=0 hours and at study end

	Time	Protein synthesis	P	Protein breakdown	P	Net Balance	P
Liver	0	415 ± 120		263 ± 50		152 ± 76	
	End	274 ± 250	0.445	108 ± 162	0.366	166 ± 231	0.836
SB-isoleucine	0	218 ± 37		109 ± 25		98 ± 33	
	End	839 ± 221	0.038	157 ± 204	0.412	682 ± 165	0.010
Leg	0	117 ± 52		137 ± 51		-20 ± 19	
	End	372 ± 211	0.189	288 ± 175	0.232	87 ± 140	0.694
SB-isoleucine	0	-31 ± 201		196 ± 61		-185 ± 152	
	End	377 ± 135	0.209	159 ± 100	0.535	261 ± 102	0.005

Data are mean ± SEM in nmol/kg body cell mass/min. End values represent the mean values of the final hour of the amino acid infusion. Protein synthesis data of liver and kidney are corrected for hydroxylation (see methods). Statistics: p values for Mann-Whitney U test for differences within groups; no significant differences were found between groups

Example 8: Administration with LOLA reduces ammonia concentration but allows ammonia to regenerate

Patients and Methods

5 Eight patients with cirrhosis (age 56 (5.6), 5M, ALD-6; Grade 2 HE: 4; Grade 3-4 HE: 4) were treated with an infusion of LOLA (40 g over 8 hours). Blood was sampled for the measurement of ammonia and glutamine.

Results

10 The results showed that administration of LOLA resulted in a significant reduction in ammonia concentration with a concomitant rise in glutamine concentration (Figure 8). This reduction in ammonia had beneficial effects upon the severity of HE. However, when LOLA was stopped, there was a rebound increase in the circulating ammonia levels, resulting in recurrence of HE in 3 of the 6 patients that had improved.

15

Example 9: Active removal of glutamine prevents the secondary rise in ammonia concentration

Patients and Methods

20 3 patients (age 45 (4.1) 2M, ALD, all HE grade 3, HRS all 3) that were undergoing hemofiltration (CVVH) were treated with an infusion of LOLA (40 g over 8 hours). Blood was sampled for the measurement of ammonia and glutamine.

Results

25 The results showed that LOLA resulted in a reduction in ammonia concentration but the addition of dialysis prevented the concomitant increase in glutamine concentration (Figure 9). Therefore, we believe there was a sustained reduction in ammonia concentration.

30 **Example 10: Phenylacetate binds glutamine to make an excretable compound and prevents the secondary rise in ammonia**

Patients and Methods

6 patients with acute liver failure (5 non-A non-B Hepatitis) and severe encephalopathy (Grade 3-4) were treated with LOLA and phenylacetate (40g/day over 8 hours).

5

Results

There was no significant increase in glutamine concentration and ammonia levels were reduced with the combined treatment (Figure 10). No rebound increase in ammonia was observed.

10

Example 11: The effect of ornithine and phenylbutyrate in human patients with hepatic encephalopathy

Patients

15 1. Groups-3 patients per group. Total 12.

2. Inclusion criteria

- adult patients aged 18-80 years, - liver cirrhosis documented by histology or clinical criteria

20 - HE type C, - ammonia concentration of > 80 umol/L, informed consent/assent

3. Exclusion criteria

- other concomitant neurological disorder, - use of another specific ammonia lowering drug, - respiratory failure requiring mechanical ventilation and sedation, - uncontrolled
25 gastrointestinal bleeding, - hypotension requiring inotropes, overt renal failure (creatinine >2 mg/dl), hemodialysis, - extracorporeal liver support, known hypersensitivity to any of the study drugs, - pregnancy.

Assessment of Mental State

30 Grading of hepatic encephalopathy (West Haven Criteria)

Grade 0 (minimal HE)	normal mental state (one or more quantifiable abnormalities on psychometric testing)
Grade 1	trivial lack of awareness euphoria or anxiety

	shortened attention span impaired performance of addition
Grade 2	lethargy or apathy minimal disorientation for time or place subtle personality change inappropriate behaviour impaired performance of subtraction
Grade 3	somnolence to semi-stupor, but responsive to verbal stimuli confusion gross disorientation
Grade 4	coma (unresponsive to verbal or noxious stimuli)

Methods

In an open labelled study, we included 8 patients with cirrhosis and hyperammonemia. They were matched for the severity of liver disease (see Table 3).

5 They were treated with one of the following regimes for a 3 day period and observations were made for 5 days. The study groups were:

- (i) Placebo: 5% Dextrose over 4 hours;
- (ii) Ornithine alone: 20g in 500 ml, 5% dextrose between 0800 and 1200;
- (iii) Phenylbutyrate: 10g twice daily, orally (0800 and 1600); and
- 10 (iv) Ornithine + Phenylbutyrate: 20g in 500 ml, 5% dextrose between 0800 and 1200 + 10g twice daily, orally (0800 and 1600).

Patients were fasted overnight between 0000 midnight and 0800 am. They were fed intragastrically with a diet of 25KCal/Kg that included 1g/Kg protein diet starting at 0800 and finishing at midnight. Blood was sampled at 0730 am and then at 1800 hr for
15 the measurement of ammonia and glutamine. Patients were monitored closely for side effects. The drug was tolerated well in each of the groups and no adverse events were observed.

Table 3. Patient Demographics

20

	Placebo	Ornithine alone	Phenylbutyrate alone	OP
Age	P1: 47 P2: 57	P3: 46 P4: 40	P5: 56 P6: 48	P7: 52 P8: 52
Sex	P1: M P2: M	P3:F P4: F	P5:F P6: M	P7: M P8: F
Aetiology of Liver Disease	P1: HCV P2: HBV	P3: HBV P4: NASH	P5: NASH P6: HBV	P7: HBV P8: HBV
Severity of	P1: 9	P3: 13	P5: 14	P7: 14

Liver Disease (Pugh Score)	P2: 12	P4: 13	P6: 13	P8: 12
Precipitating Factor	P1: Infection P2: Infection	P3: SBP P4: Infection	P5: SBP P6: ?infection	P7: SBP P8: Infection
Severity of HE (West-Haven criteria)	P1: 2 P2: 3	P3: 3 P4: 3	P5: 3 P6: 3	P7: 3 P8: 3
Severity of HE (Glasgow coma score)	P1: 9 P2: 8	P3: 8 P4: 8	P5: 9 P6: 10	P7: 9 P8: 9
Other organ failure	P1: none P2: hypotension	P3: pre-renal, hypotension P4: hypotension	P5: none P6: pre-renal	P7: none P8: none
Dead/Alive	P1: A P2: A	P3: D P4: A	P5: A P6: A	P7: A P8: A
Complications	P1: infection, SBP P2: infection, variceal bleed	P3: HRS P4: rec. infection	P5: sepsis, ICU P6: recurrent SBP	P7: none P8: bleed, day 14

SBP: spontaneous bacterial peritonitis, Non alcoholic steatohepatitis, ICU: Intensive care support needed, HRS: hepatorenal syndrome

Results

5 Figure 11 shows that the mean ammonia levels remained largely unchanged over the period of treatment in the placebo group. In the L-Ornithine and the Phenylbutyrate group, the ammonia concentration increased from baseline values. In the group treated with both L-ornithine and Phenylbutyrate, there was a substantial reduction of ammonia. The postprandial increase in ammonia was reduced in the OP treated animals
10 in addition to the reduction in ammonia concentrations. Both patients in the OP group had improved their encephalopathy score by 2 grades by day 3, which was not observed in any of the other 6 patients.

Figure 12 shows that the mean glutamine levels remained largely unchanged over the period of treatment in the OP group despite a reduction in ammonia. There was
15 a reduction in glutamine in the Phenylbutyrate group, which may well be deleterious. In the L-Ornithine and placebo groups there was an increase in Glutamine concentrations which was markedly accentuated in the postprandial state.

Figure 13 shows the changes in mental state in the groups treated with Placebo, O, P and OP.

Example 12: The effect of ornithine, phenylbutyrate and isoleucine in human patients with hepatic encephalopathy

5 **Patients**

1. Groups- 2 patients per group. Total 6

2. Inclusion criteria

10 - Adult patients aged 18-80 years, liver cirrhosis documented by histology or clinical criteria, Child B or C, recent Gastrointestinal bleed from varices (<6 hours after presentation), informed consent/assent.

3. Exclusion criteria

15 - other concomitant neurological disorder, use of another specific ammonia lowering drug, respiratory failure requiring mechanical ventilation and sedation, uncontrolled gastrointestinal bleeding, hypotension requiring inotropes, overt renal failure (creatinine >2 mg/dl), hemodialysis, extracorporeal liver support, known hypersensitivity to any of the study drugs, pregnancy/lactation.

20 **Methods**

In an open labelled study, we included 6 patients with cirrhosis and who were admitted for management of variceal bleeding. They were matched for the severity of liver disease (see Table 4). They were treated with one of the following regimes for a 3 day period and observations were made for 5 days. The study groups were:

25 i. Placebo: 5% Dextrose over 4 hours (250 ml)

ii. Isoleucine alone: 10 gm IV in 250 ml 5% Dextrose over 2 hours in two divided doses.

30 iii. Isoleucine + Ornithine + Phenylbutyrate: Isoleucine:10 gm IV in 250 ml 5% Dextrose over 2 hours in two divided doses; Ornithine: 20g in 250 ml, 5% Dextrose (t=0; 24, 48hr); Phenylbutyrate:10g twice daily, orally (t=0, 12, 24, 36, 48 hr).

Patients were fasted overnight between 0000 midnight and 0800 am. They were fed intragastrically with a diet of 25KCal/Kg that included 1g/Kg protein diet starting at 0800 and finishing at midnight. Blood was sampled at 0730 am and then at 1800 hr for